GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: December 15, 2003, 14:53:13 ; Search time 41 Seconds
(without alignments)
1200.128 Million cell updates/sec

Title: US-09-831-805A-6
Perfect score: 310
Sequence: 1 MALRRPPRLRLCARLPDFFL.....VNYIRTDEEGDFRHKSSFVI 310

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 1107863 seqs, 158726573 residues

Word size : 0

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 100 summaries

Database : A_Geneseq_19Jun03:*
1: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	310	100.0	310	21	AAY96294	Human IGFAM-6 immu
2	209	67.4	310	21	AAB27276	Human confluency r
3	209	67.4	310	21	AAB33457	Human PRO1868 prot
4	209	67.4	310	21	AAY96735	PRO1868, an A33 an
5	209	67.4	310	22	AAM93323	Human polypeptide,
6	209	67.4	310	22	AAM93905	Human polypeptide,
7	209	67.4	310	22	AAU12440	Human PRO1868 poly
8	209	67.4	310	22	AAB80272	Human PRO1868 prot
9	209	67.4	310	22	AAB80383	Secreted protein e
10	209	67.4	310	22	AAB80408	Secreted protein e
11	209	67.4	310	22	AAB80409	Secreted protein e
12	209	67.4	310	23	ABG31401	Human PRO1868 poly
13	209	67.4	310	23	ABG91361	Novel human secret
14	209	67.4	310	23	ABG92709	Human secreted pro
15	209	67.4	310	23	ABG65296	Human albumin fusi
16	209	67.4	310	23	ABG65297	Human albumin fusi
17	209	67.4	310	23	ABG65298	Human albumin fusi
18	209	67.4	310	23	ABB95553	Human angiogenesis
19	209	67.4	310	23	ABB84947	Human PRO1868 prot
20	209	67.4	310	24	ABU69682	Novel human secret
21	209	67.4	310	24	ABU71505	Human PRO polypept
22	209	67.4	310	24	ABU71951	Human secreted/tra
23	209	67.4	310	24	ABU66838	Human PRO polypept
24	209	67.4	310	24	ABU67114	Human secreted/tra
25	209	67.4	310	24	ABU67405	Human secreted pro
26	209	67.4	310	24	ABU59919	Novel secreted and
27	209	67.4	310	24	ABU60813	Human secreted/tra
28	209	67.4	310	24	ABU64559	Human secreted/tra
29	209	67.4	310	24	ABG73314	Human PRO1868 poly
30	209	67.4	310	24	ABP71277	Human junctional a
31	209	67.4	310	24	ABU54407	Human secreted/tra
32	209	67.4	311	21	AAB38333	Human secreted pro
33	209	67.4	311	21	AAB38383	Human secreted pro
34	209	67.4	311	21	AAB38384	Human secreted pro
35	209	67.4	339	22	AAB80431	Gene #13 associate
36	207	66.8	329	23	ABP41902	Human ovarian anti
37	139	44.8	321	23	ABB06037	Human NS protein s
38	115	37.1	285	21	AAB39254	Human secreted pro
39	115	37.1	310	24	AAO16453	Human junctional a
40	108	34.8	291	22	ABG04645	Novel human diagno
41	108	34.8	404	22	ABG12109	Novel human diagno
42	104	33.5	361	22	ABG22401	Novel human diagno
43	89	28.7	89	20	AAY11472	Human 5' EST secre
44	63	20.3	267	22	ABG27038	Novel human diagno
45	51	16.5	264	22	ABG07157	Novel human diagno
46	51	16.5	301	22	ABG22399	Novel human diagno
47	38	12.3	68	22	ABG22398	Novel human diagno
48	24	7.7	310	21	AAB27272	Human confluency r
49	24	7.7	310	21	AAB27278	Murine confluency
50	8	2.6	31	22	ABG49183	Human liver peptid
51	8	2.6	31	22	ABB29193	Peptide #1844 enco
52	8	2.6	31	22	ABB34350	Peptide #1856 enco
53	8	2.6	31	22	ABB19769	Protein #1768 enco
54	8	2.6	31	22	AAM55147	Human brain expres
55	8	2.6	31	22	AAM67540	Human bone marrow
56	8	2.6	31	22	AAM15353	Peptide #1787 enco
57	8	2.6	31	22	AAM27831	Peptide #1868 enco
58	8	2.6	31	22	AAM03112	Peptide #1794 enco
59	8	2.6	31	23	ABG37134	Human peptide enco
60	8	2.6	120	21	AAG30027	Arabidopsis thalia
61	8	2.6	154	21	AAG30026	Arabidopsis thalia
62	8	2.6	190	21	AAG30025	Arabidopsis thalia
63	8	2.6	452	23	ABP65896	Bifidobacterium lo
64	8	2.6	541	23	ABP73995	Candida albicans e
65	8	2.6	784	23	ABB53716	Lactococcus lactis
66	7	2.3	7	21	AAB27269	Murine CRAM-1 tyro
67	7	2.3	12	16	AAR83341	Kb-binding random
68	7	2.3	14	16	AAR83451	Arabidopsis thalia
69	7	2.3	39	21	AAB44378	Human secreted pro
70	7	2.3	39	22	ABG51323	Human liver peptid
71	7	2.3	39	22	ABB31269	Peptide #3920 enco
72	7	2.3	39	22	ABB36477	Peptide #3983 enco
73	7	2.3	39	22	ABB21819	Protein #3818 enco
74	7	2.3	39	22	AAM57241	Human brain expres
75	7	2.3	39	22	AAM69641	Human bone marrow
76	7	2.3	39	22	AAM17457	Peptide #3891 enco
77	7	2.3	39	22	AAM29977	Peptide #4014 enco
78	7	2.3	39	22	AAM05134	Peptide #3816 enco
79	7	2.3	39	23	ABG39262	Human peptide enco
80	7	2.3	40	22	AAG74530	Human colon cancer
81	7	2.3	56	22	AAO04488	Human polypeptide
82	7	2.3	58	22	AAU49383	Propionibacterium

83	7	2.3	67	21	AAG34555	Arabidopsis thalia
84	7	2.3	70	21	AAG34554	Arabidopsis thalia
85	7	2.3	71	22	AAO11264	Human polypeptide
86	7	2.3	73	22	AAU39482	Propionibacterium
87	7	2.3	78	22	ABG29189	Novel human diagno
88	7	2.3	87	22	AAU19792	Human novel extrac
89	7	2.3	87	23	ABP48012	Human polypeptide
90	7	2.3	89	21	AAG00327	Human secreted pro
91	7	2.3	89	24	ABP58692	Human protein phos
92	7	2.3	92	21	AAG59054	Arabidopsis thalia
93	7	2.3	92	21	AAG60335	Arabidopsis thalia
94	7	2.3	97	23	ABP07319	Human ORFX protein
95	7	2.3	102	20	AAY73830	Human prostate tum
96	7	2.3	104	22	AAO09976	Human polypeptide
97	7	2.3	106	22	AAG82299	S. epidermidis ope
98	7	2.3	110	21	AAG59053	Arabidopsis thalia
99	7	2.3	110	21	AAG60334	Arabidopsis thalia
100	7	2.3	119	23	ABP40383	Staphylococcus epi

ALIGNMENTS

```
RESULT 1
AAY96294
ID   AAY96294 standard; protein; 310 AA.
XX
AC   AAY96294;
XX
DT   16-AUG-2000  (first entry)
XX
DE   Human IGFAM-6 immunoglobulin.
XX
KW   Human; immunoglobulin; IGFAM-6; IGFAM; immune disorder; cancer;
KW   infection; inflammation; haematopoiesis; AIDS; allergy.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..30
FT                   /label= signal_peptide
FT   Protein         31..310
FT                   /label= IGFAM-6
FT   Domain          46..117
FT                   /label= Ig_domain
FT   Domain          153..221
FT                   /label= Ig_domain
FT   Domain          238..260
FT                   /label= transmembrane_domain
XX
PN   WO200029583-A2.
XX
PD   25-MAY-2000.
XX
PF   19-NOV-1999;   99WO-US27566.
XX
PR   19-NOV-1998;   99US-0113635.
PR   22-DEC-1998;   98US-0113635.
PR   07-APR-1999;   99US-0128194.
XX
PA   (INCY-) INCYTE PHARM INC.
XX
PI   Yue H,  Tang YT,  Corley NC,  Guegler KJ,  Gorgone GA,  Baughn MR;
PI   Lu DAM,  Lal P,  Hillman JL,  Yang J;
XX
DR   WPI; 2000-387796/33.
DR   N-PSDB; AAA27386.
XX
PT   Immunoglobulin superfamily proteins, the agonist and antagonist of the
PT   protein is useful for preventing and treating disorders associated with
PT   altered levels of the protein such as cancer, immune system disorders
PT   -
XX
PS   Claim 1; Page 82-83; 105pp; English.
XX
CC   The present sequence is the human immunoglobulin superfamily protein
CC   IGFAM-6. Its gene was isolated from a cDNA library of leg
CC   tissue. It is expressed in reproductive, nervous and
CC   cardiovascular tissue, where cancer and inflammation are common. The
CC   gene, protein, its antibodies, agonists and antagonists are suitable for
CC   diagnosing and treating many diseases, including cancer, immune system
CC   disorders (such as inflammation, AIDS, allergies, anaemia,
CC   arteriosclerosis, asthma, atherosclerosis, cholecystitis, Crohn's
CC   disease, diabetes mellitus, emphysema, Graves' disease, hepatitis,
CC   multiple sclerosis, psoriasis, rheumatoid arthritis, scleroderma,
CC   systemic lupus erythematosus and ulcerative colitis), complications of
CC   cancer, haemodialysis and extracorporeal circulation, trauma and
CC   haematopoietic cancer (such as leukaemia) and infections caused by
CC   bacteria, viruses, fungi or parasites.
XX
SQ   Sequence   310 AA;

  Query Match             100.0%;  Score 310;  DB 21;  Length 310;
  Best Local Similarity   100.0%;  Pred. No. 6.2e-296;
  Matches  310;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 2
AAB27276
ID   AAB27276 standard; Protein; 310 AA.
XX
AC   AAB27276;
XX
DT   23-FEB-2001  (first entry)
XX
DE   Human confluency regulated adhesion molecule 1 #2.
XX
KW   Immunoglobulin superfamily; Ig Sf; vascular adhesion molecule;
KW   inflammation; cancer; wound; angiogenesis; human;
KW   confluency regulated adhesion molecule 1; CRAM-1; JAM-2.
XX
OS   Homo sapiens.
XX
PN   WO200053749-A2.
XX
PD   14-SEP-2000.
XX
PF   13-MAR-2000; 2000WO-EP02219.
XX
PR   11-MAR-1999;   99EP-0200746.
XX
PA   (RMFD-) RMF DICTAGENE SA.
```

```
XX
PI   Imhof BA,  Aurrand-Lions M;
XX
DR   WPI; 2000-587436/55.
DR   N-PSDB; AAA95306.
XX
PT   Isolated human Confluency Regulated Adhesion Molecule 1 or 2 (CRAM-1 or
PT   CRAM-2) polypeptide, useful for treatment of tumors, inflammation
PT   reactions and modulating vascular permeability -
XX
PS   Claim 2; Fig 6; 59pp; English.
XX
CC   The present sequence is the human confluency regulated adhesion molecule
CC   1 (CRAM-1, also known as JAM-2). CRAM-1 is one of the vascular adhesion
CC   proteins of the immunoglobulin superfamily (Ig Sf). The CRAM-1 protein
CC   and coding sequence can be used in the treatment of cancer, inflammation,
CC   to modulate cell-cell interactions and angiogenesis, and in the
CC   modulation of wound healing.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 21;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 3
AAB33457
ID   AAB33457 standard; Protein; 310 AA.
XX
AC   AAB33457;
XX
DT   29-JAN-2001  (first entry)
XX
DE   Human PRO1868 protein UNQ859 SEQ ID NO:193.
XX
KW   Human; immune related disease; diagnosis; antiinflammatory; cardiant;
KW   dermatological; antiarthritic; antirheumatic; immunosuppressive;
KW   haemostatic; antithyroid; antidiabetic; nootropic; neuroprotective;
KW   antianaemic; hepatotropic; virucide; antipsoriatic; antiallergic;
KW   antiasthmatic; systemic lupus erythematosus; rheumatoid arthritis;
KW   osteoarthritis; spondyloarthropathy; systemic sclerosis; sarcoidosis;
KW   idiopathic inflammatory myopathy; Sjogren's syndrome; thyroiditis;
KW   systemic vasculitis; autoimmune haemolytic anaemia; diabetes mellitus;
KW   autoimmune thrombocytopaenia; immune-mediated renal disease;
KW   demyelinating disease; hepatobiliary disease; Whipple's disease;
KW   inflammatory bowel disease; gluten-sensitive enteropathy;
KW   autoimmune disease; immune-mediated skin disease; allergic disease;
KW   immunological disease; transplantation associated disease;
KW   graft rejection; graft-versus-host-disease.
XX
OS   Homo sapiens.
XX
PN   WO200053758-A2.
XX
PD   14-SEP-2000.
XX
PF   02-MAR-2000; 2000WO-US05841.
XX
PR   08-MAR-1999;   99WO-US05028.
PR   10-MAR-1999;   99US-0123618.
PR   12-MAR-1999;   99US-0123957.
PR   23-MAR-1999;   99US-0125775.
PR   12-APR-1999;   99US-0128849.
PR   20-APR-1999;   99WO-US08615.
PR   28-APR-1999;   99US-0131445.
PR   04-MAY-1999;   99US-0132371.
PR   14-MAY-1999;   99US-0134287.
PR   02-JUN-1999;   99WO-US12252.
PR   23-JUN-1999;   99US-0141037.
PR   20-JUL-1999;   99US-0144758.
PR   26-JUL-1999;   99US-0145698.
PR   28-JUL-1999;   99US-0146222.
PR   01-SEP-1999;   99WO-US20111.
PR   08-SEP-1999;   99WO-US20594.
PR   13-SEP-1999;   99WO-US20944.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   05-OCT-1999;   99WO-US23089.
PR   29-OCT-1999;   99US-0162506.
PR   29-NOV-1999;   99WO-US28214.
PR   30-NOV-1999;   99WO-US28313.
PR   30-NOV-1999;   99WO-US28409.
PR   01-DEC-1999;   99WO-US28301.
PR   01-DEC-1999;   99WO-US28634.
PR   02-DEC-1999;   99WO-US28551.
PR   02-DEC-1999;   99WO-US28564.
PR   02-DEC-1999;   99WO-US28565.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30999.
PR   30-DEC-1999;   99WO-US31274.
PR   05-JAN-2000; 2000WO-US00219.
PR   06-JAN-2000; 2000WO-US00277.
PR   06-JAN-2000; 2000WO-US00376.
PR   11-FEB-2000; 2000WO-US03565.
PR   18-FEB-2000; 2000WO-US04341.
PR   18-FEB-2000; 2000WO-US04342.
PR   22-FEB-2000; 2000WO-US04414.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Goddard A,  Gurney AL,  Hebert C,  Henzel W;
PI   Kabakoff RC,  Lu Y,  Pan J,  Pennica D,  Shelton DL,  Smith V;
PI   Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Yan M;
XX
DR   WPI; 2000-572271/53.
DR   N-PSDB; AAC58622.
XX
PT   Sixty four PRO polypeptides, useful in the diagnosis and treatment of
PT   immune related disorders, e.g. systemic lupus erythematosis, rheumatoid
PT   arthritis, osteoarthritis, thyroiditis and diabetes mellitus -
XX
PS   Claim 33; Fig 88; 309pp; English.
XX
CC   The present invention describes sixty four human PRO proteins which can
CC   be used in the treatment of immune related diseases. The human PRO
CC   proteins, anti-PRO antibodies, agonists and antagonists are useful for
CC   treating and diagnosing immune related disorders. The disorders are
CC   selected from systemic lupus erythematosus, rheumatoid arthritis,
CC   osteoarthritis, juvenile chronic arthritis, spondyloarthropathies,
CC   systemic sclerosis, idiopathic inflammatory myopathies, Sjogren's
CC   syndrome, systemic vasculitis, sarcoidosis, autoimmune haemolytic
```

```
CC   anaemia, autoimmune thrombocytopaenia, thyroiditis, diabetes mellitus,
CC   immune-mediated renal disease, demyelinating diseases of the central
CC   and peripheral nervous systems, hepatobiliary diseases, inflammatory
CC   bowel disease, gluten-sensitive enteropathy and Whipple's disease,
CC   autoimmune or immune-mediated skin diseases, allergic diseases,
CC   immunological diseases of the lung, and transplantation associated
CC   diseases including graft rejection and graft-versus-host-disease.
CC   AAC58397 to AAC58578 represent PCR primers and hybridisation probes used
CC   in the isolation of human PRO sequences. AAC58579 to AAC58642 and
CC   AAB33414 to AAB33477 represent human PRO polynucleotide and protein
CC   sequences given in the exemplification of the present invention.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 21;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||.
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 4
AAY96735
ID   AAY96735 standard; Protein; 310 AA.
XX
AC   AAY96735;
XX
DT   26-SEP-2000  (first entry)
XX
DE   PRO1868, an A33 antigen homologue.
XX
KW   PRO1868; A33 antigen; secreted protein; transmembrane protein;
KW   anti-inflammatory; cytostatic; recombinant production; gene therapy.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..30
FT                   /label= Signal_peptide
FT   Modified-site   26..31
FT                   /note= "N-myristoylation site"
FT   Modified-site   69..77
FT                   /note= "Tyrosine kinase phosphorylation site"
FT   Modified-site   104..107
FT                   /note= "N-glycosylation site"
FT   Modified-site   106..109
FT                   /note= "Casein kinase II phosphorylation site"
FT   Modified-site   107..110
FT                   /note= "cAMP- and cGMP-dependent protein kinase
FT                        phosphorylation site"
FT   Modified-site   192..195
FT                   /note= "N-glycosylation site"
FT   Modified-site   215..220
FT                   /note= "N-myristoylation site"
FT   Modified-site   226..231
FT                   /note= "N-myristoylation site"
FT   Domain          243..263
FT                   /label= Transmembrane_domain
FT   Modified-site   243..248
FT                   /note= "N-myristoylation site"
FT   Modified-site   244..249
FT                   /note= "N-myristoylation site"
FT   Modified-site   262..267
FT                   /note= "N-myristoylation site"
FT   Modified-site   296..299
FT                   /note= "Casein kinase II phosphorylation site"
XX
PN   WO200036102-A2.
XX
PD   22-JUN-2000.
XX
PF   01-DEC-1999;   99WO-US28634.
XX
PR   16-DEC-1998;   98US-0112851.
PR   16-DEC-1998;   98US-0113145.
PR   22-DEC-1998;   98US-0113511.
PR   12-JAN-1999;   99US-0115558.
PR   12-JAN-1999;   99US-0115565.
PR   12-JAN-1999;   99US-0115733.
PR   09-FEB-1999;   99US-0119341.
PR   10-FEB-1999;   99US-0119537.
PR   12-FEB-1999;   99US-0119965.
PR   02-JUN-1999;   99WO-US12252.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Botstein D,  Desnoyers L,  Ferrara N,  Fong S,  Gao W,  Goddard A;
PI   Gurney AL,  Pan J,  Roy MA,  Stewart TA,  Tumas D,  Watanabe CK;
PI   Wood WI;
XX
DR   WPI; 2000-431586/37.
DR   N-PSDB; AAA51265.
XX
PT   Isolated nucleic acid molecule encodes a PRO polypeptide which is a
PT   transmembrane polypeptide
XX
PS   Claim 1; Fig 14; 154pp; English.
XX
CC   This is PRO1868, a putative homologue of A33 antigen, a known
CC   colorectal cancer-associated marker. The invention concerns novel
CC   secreted and transmembrane proteins, designated PRO polypeptides. The
CC   cDNA and gene sequences are useful in the recombinant production of PRO
CC   polypeptides, as a hybridization probe to screen libraries to isolate
CC   cDNAs with sequence identity to PRO polypeptides or to map the gene
CC   encoding the PRO polypeptides and analyzing genetic disorders. The
CC   cDNA/gene can also be used to produce transgenic animals useful for the
CC   development and screening of therapeutically useful reagents. They can
CC   also be used in gene therapy, e.g. to replace a defective gene.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 21;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
```

```
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
                |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
                ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 5
AAM93323
ID   AAM93323 standard; Protein; 310 AA.
XX
AC   AAM93323;
XX
DT   06-NOV-2001  (first entry)
XX
DE   Human polypeptide, SEQ ID NO: 2845.
XX
KW   Human; full length cDNA; cDNA synthesis; oligo-capping.
XX
OS   Homo sapiens.
XX
PN   EP1130094-A2.
XX
PD   05-SEP-2001.
XX
PF   07-JUL-2000; 2000EP-0114089.
XX
PR   08-JUL-1999;   99JP-0194486.
PR   11-JAN-2000; 2000JP-0118774.
PR   02-MAY-2000; 2000JP-0183765.
XX
PA   (HELI-) HELIX RES INST.
XX
PI   Ota T,  Nishikawa T,  Isogai T,  Hayashi K,  Ishii S,  Kawai Y;
PI   Wakamatsu A,  Sugiyama T,  Nagai K,  Kojima S,  Otsuki T,  Koga H;
XX
DR   WPI; 2001-524255/58.
DR   N-PSDB; AAK94243.
XX
PT   830 Primers useful for synthesizing full length cDNA clones and their
PT   use in genetic manipulation -
XX
PS   Claim 8; SEQ ID NO 2845; 1380pp + sequence listing; English.
XX
CC   The invention relates to primers for synthesising full length cDNA
CC   clones. 830 cDNA molecules encoding a human protein have been
CC   isolated and nucleotide sequences of 5'- and 3'-ends of the cDNA
CC   molecules have been determined. Primers for synthesising the full length
CC   cDNA are useful for clarifying the function of the protein encoded by
CC   the cDNA. The full length clones were obtained by construction of full
CC   length enriched cDNA libraries that were synthesised by the oligo-capping
CC   method. The primers enable the production of the full length cDNA easily
CC   without any special methods. The present sequence is a polypeptide
CC   encoded by a full length human cDNA of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in CD-ROM format directly from EPO.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 22;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
                |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
                ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 6
AAM93905
ID   AAM93905 standard; Protein; 310 AA.
XX
AC   AAM93905;
XX
DT   06-NOV-2001  (first entry)
XX
DE   Human polypeptide, SEQ ID NO: 4051.
XX
KW   Human; full length cDNA; cDNA synthesis; oligo-capping.
XX
OS   Homo sapiens.
XX
PN   EP1130094-A2.
XX
PD   05-SEP-2001.
XX
PF   07-JUL-2000; 2000EP-0114089.
XX
PR   08-JUL-1999;   99JP-0194486.
PR   11-JAN-2000; 2000JP-0118774.
PR   02-MAY-2000; 2000JP-0183765.
XX
PA   (HELI-) HELIX RES INST.
XX
PI   Ota T,  Nishikawa T,  Isogai T,  Hayashi K,  Ishii S,  Kawai Y;
PI   Wakamatsu A,  Sugiyama T,  Nagai K,  Kojima S,  Otsuki T,  Koga H;
XX
DR   WPI; 2001-524255/58.
DR   N-PSDB; AAK94867.
XX
PT   830 Primers useful for synthesizing full length cDNA clones and their
PT   use in genetic manipulation -
XX
PS   Claim 8; SEQ ID NO 4051; 1380pp + sequence listing; English.
XX
CC   The invention relates to primers for synthesising full length cDNA
CC   clones. 830 cDNA molecules encoding a human protein have been
CC   isolated and nucleotide sequences of 5'- and 3'-ends of the cDNA
CC   molecules have been determined. Primers for synthesising the full length
CC   cDNA are useful for clarifying the function of the protein encoded by
CC   the cDNA. The full length clones were obtained by construction of full
CC   length enriched cDNA libraries that were synthesised by the oligo-capping
CC   method. The primers enable the production of the full length cDNA easily
CC   without any special methods. The present sequence is a polypeptide
CC   encoded by a full length human cDNA of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in CD-ROM format directly from EPO.
```

```
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 22;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 7
AAU12440
ID   AAU12440 standard; Protein; 310 AA.
XX
AC   AAU12440;
XX
DT   24-OCT-2001  (first entry)
XX
DE   Human PRO1868 polypeptide sequence.
XX
KW   Human secretory and transmembrane; PRO; mammalian; cancer; lung;
KW   breast; prostate; cervical; tumour necrosis factor-alpha; TNF-alpha;
KW   cartilage; ear; proliferation; glucose; free fatty acid; skeletal muscle;
KW   adipocyte; A-peptide; factor VIIA; gene therapy.
XX
OS   Homo sapiens.
XX
PN   WO200140466-A2.
XX
PD   07-JUN-2001.
XX
PF   01-DEC-2000; 2000WO-US32678.
XX
PR   01-DEC-1999;   99WO-US28301.
PR   01-DEC-1999;   99WO-US28634.
PR   02-DEC-1999;   99WO-US28551.
PR   02-DEC-1999;   99WO-US28564.
PR   02-DEC-1999;   99WO-US28565.
PR   09-DEC-1999;   99US-0170262.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   20-DEC-1999;   99WO-US30999.
PR   30-DEC-1999;   99WO-US31243.
PR   06-JAN-2000; 2000WO-US00277.
PR   06-JAN-2000; 2000WO-US00376.
PR   11-FEB-2000; 2000WO-US03565.
PR   18-FEB-2000; 2000WO-US04341.
PR   18-FEB-2000; 2000WO-US04342.
PR   22-FEB-2000; 2000WO-US04414.
PR   24-FEB-2000; 2000WO-US04914.
PR   24-FEB-2000; 2000WO-US05004.
PR   01-MAR-2000; 2000WO-US05601.
PR   20-MAR-2000; 2000WO-US07377.
PR   21-MAR-2000; 2000WO-US07532.
PR   30-MAR-2000; 2000WO-US08439.
PR   17-MAY-2000; 2000WO-US13705.
PR   22-MAY-2000; 2000WO-US14042.
PR   30-MAY-2000; 2000WO-US14941.
PR   02-JUN-2000; 2000WO-US15264.
PR   10-NOV-2000; 2000WO-US30873.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2001-408281/43.
DR   N-PSDB; AAS21512.
XX
PT   Isolated, secretory and transmembrane PRO polypeptide used to detect
PT   other PRO polypeptides, link bioactive molecules to cells expressing
PT   PRO polypeptides, and detect the presence of mammalian tumours e.g.
PT   lung, breast, prostate, cervical  -
XX
PS   Claim 12; Fig 538; 813pp; English.
XX
CC   AAU12172-AAU12446 represent novel human secretory and transmembrane
CC   PRO polypeptides. The PRO polypeptides are useful to detect other
CC   PRO polypeptides, to link bioactive molecules to cells expressing
CC   PRO polypeptides, to modulate biological activities of cells expressing
CC   PRO polypeptides, and to detect the presence of mammalian lung, colon,
CC   breast, prostate, rectal, cervical or liver tumours by comparing PRO
CC   polypeptide expression in a cell sample to that in a control sample.
CC   Some of the 275 sequences are also useful to stimulate the release of
CC   tumour necrosis factor-alpha (TNF-alpha) from human blood, the
CC   proliferation or differentiation of chondrocytes, the proliferation or
CC   gene expression in pericyte cells, the release of proteoglycans from
CC   cartilage, the proliferation of inner ear utricular supporting cells or
CC   of T-lymphocytes, the release of a cytokine from peripheral blood
CC   monocytes (PBMCs), or the proliferation of endothelial cells. Some of
CC   the PRO polypeptides may modulate glucose or free fatty acid uptake by
CC   skeletal muscle cells or by adipocytes; or inhibit binding of A-peptide
CC   to factor VIIA. The PRO polypeptides can be used in assays to identify
CC   molecules involved in binding interactions. The polynucleotides encoding
CC   PRO polypeptides can be used to generate probes, antisense RNA/DNA,
CC   transgenic or knock out animals and can be used in gene therapy.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 22;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
```

```
Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 8
AAB80272
ID   AAB80272 standard; Protein; 310 AA.
XX
AC   AAB80272;
XX
DT   24-APR-2001  (first entry)
XX
DE   Human PRO1868 protein.
XX
KW   Human; PRO; dermatological; antipsoriatic; cytostatic; antiinflammatory;
KW   antiparkinsonian nootropic; neuroprotective; vulnerary; cardiant;
KW   antiangiogenic; vasotropic; antiasthmatic; antirheumatic; cancer;
KW   antiarthritic; antiinfertility; antidiabetic; antiviral; diabetes;
KW   ophthalmological; gene therapy; skin disease; gastrointestinal disorder;
KW   ischaemia; inflammation.
XX
OS   Homo sapiens.
XX
PN   WO200104311-A1.
XX
PD   18-JAN-2001.
XX
PF   22-FEB-2000; 2000WO-US04414.
XX
PR   07-JUL-1999;   99US-0143048.
PR   26-JUL-1999;   99US-0145698.
PR   28-JUL-1999;   99US-0146222.
PR   08-SEP-1999;   99WO-US20594.
PR   13-SEP-1999;   99WO-US20944.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   05-OCT-1999;   99WO-US23089.
PR   29-NOV-1999;   99WO-US28214.
PR   30-NOV-1999;   99WO-US28313.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   20-DEC-1999;   99WO-US30999.
PR   05-JAN-2000;   99WO-US00219.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Botstein D,  Desnoyers L,  Eaton DL,  Ferrara N;
PI   Filvaroff E,  Fong S,  Gao W,  Gerber H,  Gerritsen ME,  Goddard A;
PI   Godowski PJ,  Grimaldi CJ,  Gurney AL,  Hillan KJ,  Kljavin IJ;
PI   Mather JP,  Pan J,  Paoni NF,  Roy MA,  Stewart TA,  Tumas D;
PI   Williams PM,  Wood WI;
XX
DR   WPI; 2001-081051/09.
DR   N-PSDB; AAF72433.
XX
PT   Sixty one nucleic acids encoding PRO polypeptides which are useful in
PT   the treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung
PT   squamous cell carcinoma) and neurodegenerative diseases (e.g.
PT   Alzheimer's disease) -
XX
PS   Claim 1; Fig 124; 393pp; English.
XX
CC   The present sequence is one of sixty one novel secreted and
CC   transmembrane PRO polypeptides. The PRO polypeptides are
CC   useful for treating skin diseases (e.g. psoriasis), cancers (e.g. lung
CC   squamous cell carcinoma), gastrointestinal disorders (e.g.
CC   enterocolitis), neurodegenerative diseases (e.g. Alzheimer's disease,
CC   Parkinson's disease), wound repair, cardiovascular disorders (e.g.
CC   endometrial bleeding angiogenesis, ischaemias such as coronary
CC   ischaemia, atherosclerosis), inflammatory disorders (e.g. asthma,
CC   rheumatoid arthritis, multiple sclerosis), infertility, AIDS and
CC   diabetes and retinal disorders such as retinitis pigmentosum.
CC   The PRO nucleic acids have applications in molecular biology, including
CC   use as hybridization probes, and in chromosome and gene mapping.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 22;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 9
AAB80383
ID   AAB80383 standard; protein; 310 AA.
XX
AC   AAB80383;
XX
DT   24-APR-2001  (first entry)
XX
DE   Secreted protein encoded by gene #13.
XX
KW   Secreted protein; human; autoimmune; hyperproliferation;
KW   cardiovascular; cerebrovascular; infection; food.
XX
OS   Homo sapiens.
XX
PN   WO200107459-A1.
XX
PD   01-FEB-2001.
XX
PF   20-JUL-2000; 2000WO-US19735.
XX
PR   23-JUL-1999;   99US-0145220.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Ruben SM,  Ebner R,  Duan RD,  Ni J,  Soppet DR,  Moore PA;
PI   Shi Y,  Lafleur DW,  Olsen HS,  Birse CE,  Komatsoulis GA;
XX
DR   WPI; 2001-123261/13.
XX
PT   New isolated nucleic acid encoding 29 secreted proteins, for
PT   diagnosing, preventing and treating e.g. autoimmune,
PT   hyperproliferative, cardiovascular, and ocular diseases or disorders
PT   and microorganism infections  -
XX
PS   Claim 11; Page 538-539; 601pp; English.
XX
CC   The present invention relates to 29 human secreted proteins. The
CC   invention is used to prevent autoimmune diseases e.g. rheumatoid
```

```
CC   arthritis, hyperproliferative disorders e.g. neoplasms of the
CC   breast or liver, cardiovascular disorders e.g. cardiac arrest,
CC   cerebrovascular disorders e.g. cerebral ischemia, angiogenesis,
CC   nervous system disorders e.g. Alzheimer's disease, infections
CC   caused by bacteria, viruses and fungi and ocular disorders e.g.
CC   corneal infection. Also used in food preparations.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 22;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 10
AAB80408
ID   AAB80408 standard; protein; 310 AA.
XX
AC   AAB80408;
XX
DT   24-APR-2001  (first entry)
XX
DE   Secreted protein encoded by gene #38.
XX
KW   Secreted protein; human; autoimmune; hyperproliferation;
KW   cardiovascular; cerebrovascular; infection; food.
XX
OS   Homo sapiens.
XX
PN   WO200107459-A1.
XX
PD   01-FEB-2001.
XX
PF   20-JUL-2000; 2000WO-US19735.
XX
PR   23-JUL-1999;   99US-0145220.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Ruben SM,  Ebner R,  Duan RD,  Ni J,  Soppet DR,  Moore PA;
PI   Shi Y,  Lafleur DW,  Olsen HS,  Birse CE,  Komatsoulis GA;
XX
DR   WPI; 2001-123261/13.
XX
PT   New isolated nucleic acid encoding 29 secreted proteins, for
PT   diagnosing, preventing and treating e.g. autoimmune,
PT   hyperproliferative, cardiovascular, and ocular diseases or disorders
PT   and microorganism infections  -
XX
PS   Claim 11; Page 557-558; 601pp; English.
XX
CC   The present invention relates to 29 human secreted proteins. The
CC   invention is used to prevent autoimmune diseases e.g. rheumatoid
CC   arthritis, hyperproliferative disorders e.g. neoplasms of the
CC   breast or liver, cardiovascular disorders e.g. cardiac arrest,
CC   cerebrovascular disorders e.g. cerebral ischemia, angiogenesis,
CC   nervous system disorders e.g. Alzheimer's disease, infections
CC   caused by bacteria, viruses and fungi and ocular disorders e.g.
CC   corneal infection. Also used in food preparations.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 22;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 11
AAB80409
ID   AAB80409 standard; protein; 310 AA.
XX
AC   AAB80409;
XX
DT   24-APR-2001  (first entry)
XX
DE   Secreted protein encoded by gene #39.
XX
KW   Secreted protein; human; autoimmune; hyperproliferation;
KW   cardiovascular; cerebrovascular; infection; food.
XX
OS   Homo sapiens.
XX
PN   WO200107459-A1.
XX
PD   01-FEB-2001.
XX
PF   20-JUL-2000; 2000WO-US19735.
XX
PR   23-JUL-1999;   99US-0145220.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Ruben SM,  Ebner R,  Duan RD,  Ni J,  Soppet DR,  Moore PA;
PI   Shi Y,  Lafleur DW,  Olsen HS,  Birse CE,  Komatsoulis GA;
XX
DR   WPI; 2001-123261/13.
XX
PT   New isolated nucleic acid encoding 29 secreted proteins, for
```

```
PT   diagnosing, preventing and treating e.g. autoimmune,
PT   hyperproliferative, cardiovascular, and ocular diseases or disorders
PT   and microorganism infections  -
XX
PS   Claim 11; Page 559-560; 601pp; English.
XX
CC   The present invention relates to 29 human secreted proteins. The
CC   invention is used to prevent autoimmune diseases e.g. rheumatoid
CC   arthritis, hyperproliferative disorders e.g. neoplasms of the
CC   breast or liver, cardiovascular disorders e.g. cardiac arrest,
CC   cerebrovascular disorders e.g. cerebral ischemia, angiogenesis,
CC   nervous system disorders e.g. Alzheimer's disease, infections
CC   caused by bacteria, viruses and fungi and ocular disorders e.g.
CC   corneal infection. Also used in food preparations.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 22;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 12
ABG31401
ID   ABG31401 standard; Protein; 310 AA.
XX
AC   ABG31401;
XX
DT   29-NOV-2002  (first entry)
XX
DE   Human PRO1868 polypeptide.
XX
KW   Human; secreted and transmembrane polypeptide; PRO polypeptide;
KW   T-lymphocyte proliferation; inflammatory disease; rheumatoid arthritis;
KW   inflammatory bowel disease; Sjogren's syndrome; thyroiditis;
KW   autoimmune haemolytic anaemia; diabetes mellitus; multiple sclerosis;
KW   hepatitis; contact dermatitis; allergic disease; psoriasis; virucide;
KW   immune related disease; kidney disease; antiinflammatory; antithyroid;
KW   antirheumatic; antiarthritic; immunosuppressive; antianaemic;
KW   antidiabetic; neuroprotective; hepatotropic; antiinflammatory;
KW   dermatological; antiallergic; antipsoriatic; PRO1868.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..30
FT                   /label= Signal_peptide
FT   Modified-site   26..31
FT                   /note= "N-myristoylation site"
FT   Protein         31..310
FT                   /label= Mature_PRO1868
FT   Modified-site   69..77
FT                   /note= "Tyrosine kinase phosphorylation site"
FT   Modified-site   104..107
FT                   /note= "N-glycosylation site"
FT   Modified-site   106..109
FT                   /note= "Casein kinase II phosphorylation site"
FT   Modified-site   107..110
FT                   /note= "cAMP- and cGMP-dependent protein kinase
FT                         phosphorylation site"
FT   Modified-site   192..195
FT                   /note= "N-glycosylation site"
FT   Modified-site   215..220
FT                   /note= "N-myristoylation site"
FT   Modified-site   226..231
FT                   /note= "N-myristoylation site"
FT   Domain          243..263
FT                   /label= Transmembrane_domain
FT   Modified-site   243..248
FT                   /note= "N-myristoylation site"
FT   Modified-site   244..249
FT                   /note= "N-myristoylation site"
FT   Modified-site   262..267
FT                   /note= "N-myristoylation site"
FT   Modified-site   296..299
FT                   /note= "Casein kinase II phosphorylation site"
XX
PN   US2002098507-A1.
XX
PD   25-JUL-2002.
XX
PF   27-DEC-2001; 2001US-0033326.
XX
PR   02-JUN-1999;   99WO-US12252.
PR   01-DEC-1999;   99WO-US28634.
PR   02-DEC-1999;   99WO-US28551.
PR   11-FEB-2000; 2000WO-US03565.
PR   22-FEB-2000; 2000WO-US04414.
PR   02-MAR-2000; 2000WO-US05841.
PR   30-MAR-2000; 2000WO-US08439.
PR   30-MAY-2000; 2000WO-US14941.
PR   02-JUN-2000; 2000WO-US15264.
PR   01-DEC-2000; 2000WO-US32678.
PR   16-DEC-1998;   98US-113145P.
PR   22-DEC-1998;   98US-113511P.
PR   12-JAN-1999;   99US-115558P.
PR   12-JAN-1999;   99US-115565P.
PR   12-JAN-1999;   99US-115733P.
PR   09-FEB-1999;   99US-119341P.
PR   10-FEB-1999;   99US-119537P.
PR   12-FEB-1999;   99US-119965P.
PR   29-OCT-1999;   99US-162506P.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Botstein D,  Desnoyers L,  Ferrara N,  Fong S,  Gao W,  Goddard A;
PI   Gurney AL,  Pan J,  Roy MA,  Stewart TA,  Tumas D,  Watanabe CK;
PI   Wood WI;
XX
DR   WPI; 2002-673823/72.
DR   N-PSDB; ABS53477.
XX
PT   Novel PRO polypeptides and nucleic acids encoding the polypeptides,
PT   useful for preparing a medicament for the treatment of inflammatory and
PT   immune related disorders -
XX
PS   Claim 12; Fig 14; 125pp; English.
XX
CC   The present invention relates to the isolation of novel human
CC   secreted and transmembrane polypeptides, designated PRO polypeptides,
CC   and the polynucleotide sequences encoding them. The PRO polypeptides
CC   of the invention include PRO1800, PRO539, PRO982, PRO1434, PRO1863,
```

```
CC   PRO1917, PRO1868, PRO3434 and PRO1927. The PRO polypeptides can
CC   inhibit the stimulation of T-lymphocyte proliferation. The PRO
CC   polypeptides are useful for the diagnosis and treatment of inflammatory
CC   diseases (e.g. inflammatory bowel disease, rheumatoid arthritis,
CC   Sjogren's syndrome, autoimmune haemolytic anaemia, thyroiditis, diabetes
CC   mellitus, multiple sclerosis, hepatitis, contact dermatitis, allergic
CC   diseases and psoriasis), immune related diseases, and kidney diseases
CC   in humans. The present sequence represents human PRO1868 polypeptide.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 23;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 13
ABG91361
ID   ABG91361 standard; Protein; 310 AA.
XX
AC   ABG91361;
XX
DT   29-NOV-2002  (first entry)
XX
DE   Novel human secreted protein #7.
XX
KW   Human; secreted protein; transmembrane protein; gene mapping;
KW   transgenic; immunogenic.
XX
OS   Homo sapiens.
XX
PN   US2002098505-A1.
XX
PD   25-JUL-2002.
XX
PF   28-DEC-2001; 2001US-0033246.
XX
PR   02-JUN-1999;   99WO-US12252.
PR   01-DEC-1999;   99WO-US28634.
PR   02-DEC-1999;   99WO-US28551.
PR   11-FEB-2000; 2000WO-US03565.
PR   22-FEB-2000; 2000WO-US04414.
PR   02-MAR-2000; 2000WO-US05841.
PR   30-MAR-2000; 2000WO-US08439.
PR   30-MAY-2000; 2000WO-US14941.
PR   02-JUN-2000; 2000WO-US15264.
PR   01-DEC-2000; 2000WO-US32678.
PR   16-DEC-1998;   98US-113145P.
PR   22-DEC-1998;   98US-113511P.
PR   12-JAN-1999;   99US-115558P.
PR   12-JAN-1999;   99US-115565P.
PR   12-JAN-1999;   99US-115733P.
PR   09-FEB-1999;   99US-119341P.
PR   10-FEB-1999;   99US-119537P.
PR   12-FEB-1999;   99US-119965P.
PR   29-OCT-1999;   99US-162506P.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Botstein D,  Desnoyers L,  Ferrara N,  Fong S,  Gao W,  Goddard A;
PI   Gurney AL,  Pan J,  Roy MA,  Stewart TA,  Tumas D,  Watanabe CK;
PI   Wood WI;
XX
DR   WPI; 2002-665999/71.
DR   N-PSDB; ABS67460.
XX
PT   New human secreted and transmembrane (PRO) polypeptides, useful for
PT   treating conditions requiring PRO polypeptides, for screening PRO
PT   antagonists and agonists useful as drug candidates -
XX
PS   Claim 12; Figure 14; 125pp; English.
XX
CC   The invention relates to new human secreted and transmembrane proteins
CC   (PRO) and nucleic acids of the invention. The polypeptides can be
CC   administered therapeutically, especially by expressing encoding
CC   polynucleotides, e.g. in therapeutic compositions. They can be used to
CC   screen for PRO polypeptide antagonists and agonists useful to identify
CC   drug candidates. They can also be used to produce antibodies, useful to
CC   detect PRO polypeptides (e.g. diagnostically), purify PRO polypeptides or
CC   therapeutically (e.g. as antagonists or to target and/or deliver
CC   cytotoxic agents). The polynucleotides are useful therapeutically e.g. to
CC   produce antisense sequences to inhibit polypeptide production. They can
CC   be used to produce probes and primers useful to detect or isolate
CC   sequences encoding PRO polypeptides or similar sequences e.g. variants or
CC   sequences from other species. They are also useful for gene mapping and
CC   to generate transgenic animals. ABG91355-ABG91363 represent human PRO
CC   amino acid sequences of the invention.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 23;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 14
ABG92709
ID   ABG92709 standard; Protein; 310 AA.
```

XX
AC ABG92709;
XX
DT 18-NOV-2002 (first entry)
XX
DE Human secreted protein PRO1868.
XX
KW Human; secreted and transmembrane protein; PRO1800; PRO539;
KW PRO982; PRO1434; PRO1863; PRO1917; PRO1868; PRO3434; PRO1927;
KW inflammatory disorder; immune related disease; rheumatoid arthritis;
KW systemic lupus erythematosus; systemic sclerosis; thyroiditis;
KW autoimmune haemolytic anaemia; diabetes mellitus; infectious hepatitis;
KW psoriasis; allergic disease of the lung; graft-versus host disease;
KW tumour; gene therapy.
XX
OS Homo sapiens.
XX
PN US2002098506-A1.
XX
PD 25-JUL-2002.
XX
PF 27-DEC-2001; 2001US-0033301.
XX
PR 04-AUG-1998; 98US-095325P.
PR 16-DEC-1998; 98US-112851P.
PR 16-DEC-1998; 98US-113145P.
PR 22-DEC-1998; 98US-113511P.
PR 12-JAN-1999; 99US-115558P.
PR 12-JAN-1999; 99US-115565P.
PR 12-JAN-1999; 99US-115733P.
PR 09-FEB-1999; 99US-119341P.
PR 10-FEB-1999; 99US-119537P.
PR 12-FEB-1999; 99US-119965P.
PR 29-OCT-1999; 99US-162506P.
PR 02-JUN-1999; 99WO-US12252.
PR 01-DEC-1999; 99WO-US28634.
PR 02-DEC-1999; 99WO-US28551.
PR 11-FEB-2000; 2000WO-US03565.
PR 22-FEB-2000; 2000WO-US04414.
PR 02-MAR-2000; 2000WO-US05841.
PR 30-MAR-2000; 2000WO-US08439.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 01-DEC-2000; 2000WO-US32678.
XX
PA (GETH) GENENTECH INC.
XX
PI Botstein D, Desnoyers L, Ferrara N, Fong S, Gao W, Goddard A;
PI Gurney AL, Pan J, Roy MA, Stewart TA, Tumas D, Watanabe CK;
PI Wood WI;
XX
DR WPI; 2002-690475/74.
DR N-PSDB; ABS68392.
XX
PT Novel secreted and transmembrane polypeptides and polynucleotides
PT useful for diagnosis and treatment of inflammatory disorders and
PT immune-related diseases, and identifying modulators -
XX
PS Claim 12; Fig 14; 125pp; English.
XX
CC The invention relates to an isolated polypeptide having at least 80%
CC amino acid sequence identity to secreted and transmembrane polypeptides
CC PRO1800, PRO539, PRO982, PRO1434, PRO1863, PRO1917, PRO1868, PRO3434 or
CC PRO1927 and their encoding nucleic acids. Also included are vectors, host
CC cells and antibodies against PRO polypeptides. PRO proteins are useful
CC for identifying modulators of the polypeptide. PRO1868 useful for the
CC diagnosis and treatment of inflammatory and immune related diseases
CC including systemic lupus erythematosus, rheumatoid arthritis, systemic
CC sclerosis, autoimmune haemolytic anaemia, thyroiditis, diabetes mellitus,
CC infectious hepatitis, psoriasis, allergic diseases of the lung and
CC graft-versus host disease and tumours. Pro nucleic acids are useful for
CC constructing hybridisation probes for mapping the gene that encodes that
CC PRO and for the genetic analysis of individuals with genetic disorders,
CC and for generating transgenic animals which are useful in the development
CC and screening of therapeutically useful reagents. PRO nucleic acids are
CC also useful for gene therapy, chromosome identification, and tissue
CC typing. PRO proteins are useful as molecular weight markers for protein
CC electrophoresis purposes. The anti-PRO antibodies are useful in
CC diagnostic assays for PRO, e.g. detecting its expression in specific
CC cells, tissues or serum and for affinity purification of PRO.
CC The present sequence represents a PRO protein.
XX
SQ Sequence 310 AA;

Query Match 67.4%; Score 209; DB 23; Length 310;
Best Local Similarity 99.7%; Pred. No. 1e-196;
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310
```

RESULT 15
ABG65296
ID ABG65296 standard; Protein; 310 AA.
XX
AC ABG65296;
XX
DT 27-AUG-2002 (first entry)
XX
DE Human albumin fusion protein #1971.
XX
KW Albumin fusion protein; therapeutic protein X; human albumin; HA;
KW human serum albumin; HSA; cancer; reproductive disorder;
KW digestive disorder; immune disorder; endocrine disorder;
KW haematopoietic disorder; neural disorder; connective disorder;
KW cytostatic; antiinfertility; antiinflammatory; antiulcer;
KW immunomodulator; anti-HIV; antidiabetic; haemostatic; nootropic;
KW neuroprotective; antiparkinsonian; antimicrobial; neuroleptic;
KW osteopathic; antiarthritic.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200177137-A1.
XX
PD 18-OCT-2001.
XX
PF 12-APR-2001; 2001WO-US11988.
XX
PR 12-APR-2000; 2000US-229358P.
PR 25-APR-2000; 2000US-199384P.
PR 21-DEC-2000; 2000US-256931P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.

```
XX
PI   Rosen CA,  Haseltine WA;
XX
DR   WPI; 2002-010886/01.
XX
PT   New fusion protein for treating disease e.g. diabetes comprises an
PT   albumin fused to a therapeutic protein -
XX
PS   Claim 1; Page 1893-1894; 2102pp; English.
XX
CC   The present invention relates to albumin fusion proteins comprising a
CC   therapeutic protein X and human albumin (HA, also known as human serum
CC   albumin, HSA). The proteins are useful for treating a disease or
CC   disorder that may be modulated by therapeutic protein X. The albumin
CC   extends the shelf-life of protein X, and may increase its biological
CC   in vitro/in vivo activity. The protein is useful for treating and
CC   diagnosing disorders such as cancer, reproductive disorders, digestive
CC   disorders (e.g. Crohn's disease, ulcerative colitis), immune disorders
CC   (e.g. acquired immunodeficiency syndrome, AIDS), endocrine disorders
CC   (e.g. diabetes), haematopoietic disorders, neural disorders
CC   (e.g. Alzheimer's, Parkinson's, Creutzfeldt-Jacob disease,
CC   encephalomyelitis, meningitis, schizophrenia), and connective disorders
CC   (e.g. osteoporosis, arthritis). ABG63326-ABG65518 represent albumin
CC   fusion proteins of the invention.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 23;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 16
ABG65297
ID   ABG65297 standard; Protein; 310 AA.
XX
AC   ABG65297;
XX
DT   27-AUG-2002  (first entry)
XX
DE   Human albumin fusion protein #1972.
XX
KW   Albumin fusion protein; therapeutic protein X; human albumin; HA;
KW   human serum albumin; HSA; cancer; reproductive disorder;
KW   digestive disorder; immune disorder; endocrine disorder;
KW   haematopoietic disorder; neural disorder; connective disorder;
KW   cytostatic; antiinfertility; antiinflammatory; antiulcer;
KW   immunomodulator; anti-HIV; antidiabetic; haemostatic; nootropic;
KW   neuroprotective; antiparkinsonian; antimicrobial; neuroleptic;
KW   osteopathic; antiarthritic.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200177137-A1.
XX
PD   18-OCT-2001.
XX
PF   12-APR-2001; 2001WO-US11988.
XX
PR   12-APR-2000; 2000US-229358P.
PR   25-APR-2000; 2000US-199384P.
PR   21-DEC-2000; 2000US-256931P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Haseltine WA;
XX
DR   WPI; 2002-010886/01.
XX
PT   New fusion protein for treating disease e.g. diabetes comprises an
PT   albumin fused to a therapeutic protein -
XX
PS   Claim 1; Page 1895; 2102pp; English.
XX
CC   The present invention relates to albumin fusion proteins comprising a
CC   therapeutic protein X and human albumin (HA, also known as human serum
CC   albumin, HSA). The proteins are useful for treating a disease or
CC   disorder that may be modulated by therapeutic protein X. The albumin
CC   extends the shelf-life of protein X, and may increase its biological
CC   in vitro/in vivo activity. The protein is useful for treating and
CC   diagnosing disorders such as cancer, reproductive disorders, digestive
CC   disorders (e.g. Crohn's disease, ulcerative colitis), immune disorders
CC   (e.g. acquired immunodeficiency syndrome, AIDS), endocrine disorders
CC   (e.g. diabetes), haematopoietic disorders, neural disorders
CC   (e.g. Alzheimer's, Parkinson's, Creutzfeldt-Jacob disease,
CC   encephalomyelitis, meningitis, schizophrenia), and connective disorders
CC   (e.g. osteoporosis, arthritis). ABG63326-ABG65518 represent albumin
CC   fusion proteins of the invention.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 23;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 17
```

```
ABG65298
ID   ABG65298 standard; Protein; 310 AA.
XX
AC   ABG65298;
XX
DT   27-AUG-2002  (first entry)
XX
DE   Human albumin fusion protein #1973.
XX
KW   Albumin fusion protein; therapeutic protein X; human albumin; HA;
KW   human serum albumin; HSA; cancer; reproductive disorder;
KW   digestive disorder; immune disorder; endocrine disorder;
KW   haematopoietic disorder; neural disorder; connective disorder;
KW   cytostatic; antiinfertility; antiinflammatory; antiulcer;
KW   immunomodulator; anti-HIV; antidiabetic; haemostatic; nootropic;
KW   neuroprotective; antiparkinsonian; antimicrobial; neuroleptic;
KW   osteopathic; antiarthritic.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200177137-A1.
XX
PD   18-OCT-2001.
XX
PF   12-APR-2001; 2001WO-US11988.
XX
PR   12-APR-2000; 2000US-229358P.
PR   25-APR-2000; 2000US-199384P.
PR   21-DEC-2000; 2000US-256931P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Haseltine WA;
XX
DR   WPI; 2002-010886/01.
XX
PT   New fusion protein for treating disease e.g. diabetes comprises an
PT   albumin fused to a therapeutic protein -
XX
PS   Claim 1; Page 1896-1897; 2102pp; English.
XX
CC   The present invention relates to albumin fusion proteins comprising a
CC   therapeutic protein X and human albumin (HA, also known as human serum
CC   albumin, HSA). The proteins are useful for treating a disease or
CC   disorder that may be modulated by therapeutic protein X. The albumin
CC   extends the shelf-life of protein X, and may increase its biological
CC   in vitro/in vivo activity. The protein is useful for treating and
CC   diagnosing disorders such as cancer, reproductive disorders, digestive
CC   disorders (e.g. Crohn's disease, ulcerative colitis), immune disorders
CC   (e.g. acquired immunodeficiency syndrome, AIDS), endocrine disorders
CC   (e.g. diabetes), haematopoietic disorders, neural disorders
CC   (e.g. Alzheimer's, Parkinson's, Creutzfeldt-Jacob disease,
CC   encephalomyelitis, meningitis, schizophrenia), and connective disorders
CC   (e.g. osteoporosis, arthritis). ABG63326-ABG65518 represent albumin
CC   fusion proteins of the invention.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 23;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 18
ABB95553
ID   ABB95553 standard; Protein; 310 AA.
XX
AC   ABB95553;
XX
DT   19-JUL-2002  (first entry)
XX
DE   Human angiogenesis related protein PRO1868 SEQ ID NO: 262.
XX
KW   Human; angiogenesis; PRO protein; cardiovascularisation; wound; cancer;
KW   atherosclerosis; cardiac hypertrophy; gene therapy; endothelial disorder;
KW   cardiant; cytostatic; antiangiogenic; hypotensive; vulnerary;
KW   antiarteriosclerotic.
XX
OS   Homo sapiens.
XX
PN   WO200208284-A2.
XX
PD   31-JAN-2002.
XX
PF   09-JUL-2001; 2001WO-US21735.
XX
PR   20-JUL-2000; 2000US-219556P.
PR   25-JUL-2000; 2000US-220624P.
PR   25-JUL-2000; 2000US-220664P.
PR   28-JUL-2000; 2000WO-US20710.
PR   02-AUG-2000; 2000US-222695P.
PR   17-AUG-2000; 2000US-0643657.
PR   23-AUG-2000; 2000WO-US23522.
PR   24-AUG-2000; 2000WO-US23328.
PR   07-SEP-2000; 2000US-230978P.
PR   15-SEP-2000; 2000US-000000P.
PR   18-SEP-2000; 2000US-0664610.
PR   18-SEP-2000; 2000US-0665350.
PR   24-OCT-2000; 2000US-242922P.
PR   08-NOV-2000; 2000US-0709238.
PR   08-NOV-2000; 2000WO-US30952.
PR   10-NOV-2000; 2000WO-US30873.
PR   01-DEC-2000; 2000WO-US32678.
PR   20-DEC-2000; 2000US-0747259.
PR   20-DEC-2000; 2000WO-US34956.
PR   22-JAN-2001; 2001US-0767609.
PR   28-FEB-2001; 2001US-0796498.
PR   28-FEB-2001; 2001WO-US06520.
PR   01-MAR-2001; 2001WO-US06666.
PR   09-MAR-2001; 2001US-0802706.
PR   14-MAR-2001; 2001US-0808689.
PR   22-MAR-2001; 2001US-0816744.
PR   05-APR-2001; 2001US-0828366.
PR   10-MAY-2001; 2001US-0854208.
PR   10-MAY-2001; 2001US-0854280.
PR   25-MAY-2001; 2001US-0866028.
PR   25-MAY-2001; 2001US-0866034.
PR   25-MAY-2001; 2001WO-US17092.
PR   30-MAY-2001; 2001US-0870574.
PR   30-MAY-2001; 2001WO-US17443.
PR   01-JUN-2001; 2001WO-US17800.
```

```
PR   20-JUN-2001; 2001WO-US19692.
PR   28-JUN-2001; 2001WO-US00000.
XX
PA   (GETH ) GENENTECH INC.
PA   (BAKE/) BAKER K P.
PA   (FERR/) FERRARA N.
PA   (GERB/) GERBER H.
PA   (GERR/) GERRITSEN M E.
PA   (GODD/) GODDARD A.
PA   (GODO/) GODOWSKI P J.
PA   (GURN/) GURNEY A L.
PA   (HILL/) HILLAN K J.
PA   (MARS/) MARSTERS S A.
PA   (PANJ/) PAN J.
PA   (PAON/) PAONI N F.
PA   (STEP/) STEPHAN J F.
PA   (WATA/) WATANABE C K.
PA   (WILL/) WILLIAMS P M.
PA   (WOOD/) WOOD W I.
XX
PI   Baker KP,  Ferrara N,  Gerber H,  Gerritsen ME,  Goddard A;
PI   Godowski PJ,  Gurney AL,  Hillan KJ,  Marsters SA,  Pan J,  Paoni NF;
PI   Stephan JF,  Watanabe CK,  Williams PM,  Wood WI,  Ye W;
XX
DR   WPI; 2002-171999/22.
DR   N-PSDB; ABL95691.
XX
PT   One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT   useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT   infarction), endothelial or angiogenic disorders in a mammal -
XX
PS   Claim 11; Fig 262; 567pp; English.
XX
CC   The present invention provides the protein and coding sequences of human
CC   PRO proteins. These are useful for treating or diagnosing a
CC   cardiovascular, endothelial or angiogenic disorder, including cardiac
CC   hypertrophy, trauma, cancer, age-related macular degeneration,
CC   atherosclerosis, hypertension, arterial restenosis, rheumatoid arthritis,
CC   angina, myocardial infarctions, thrombophlebitis, lymphangitis, tumour
CC   angiogenesis (such as breast carcinoma and liver carcinoma) and wound
CC   healing. The present sequence is a PRO protein of the invention.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 23;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310
```

```
RESULT 19
ABB84947
ID   ABB84947 standard; Protein; 310 AA.
XX
AC   ABB84947;
XX
DT   16-MAY-2002  (first entry)
XX
DE   Human PRO1868 protein sequence SEQ ID NO:262.
XX
KW   Human; angiogenesis; cardiant; cytostatic; antiangiogenic; hypotensive;
KW   vulnerary; antiarteriosclerotic; PRO agonist; PRO antagonist; trauma;
KW   gene therapy; cardiovascular disorder; endothelial disorder; cancer;
KW   angiogenic disorder; cardiac hypertrophy; atherosclerosis; hypertension;
KW   age-related macular degeneration; arterial restenosis; angina;
KW   rheumatoid arthritis; myocardial infarction; thrombophlebitis;
KW   lymphangitis; tumour angiogenesis; breast carcinoma; liver carcinoma;
KW   wound healing; chromosome mapping; gene mapping.
XX
OS   Homo sapiens.
XX
PN   WO200200690-A2.
XX
PD   03-JAN-2002.
XX
PF   20-JUN-2001; 2001WO-US19692.
XX
PR   23-JUN-2000; 2000US-213637P.
PR   20-JUL-2000; 2000US-219556P.
PR   25-JUL-2000; 2000US-220624P.
PR   25-JUL-2000; 2000US-220664P.
PR   28-JUL-2000; 2000WO-US20710.
PR   02-AUG-2000; 2000US-222695P.
PR   17-AUG-2000; 2000US-0643657.
PR   23-AUG-2000; 2000WO-US23522.
PR   24-AUG-2000; 2000WO-US23328.
PR   07-SEP-2000; 2000US-230978P.
PR   18-SEP-2000; 2000US-0664610.
PR   18-SEP-2000; 2000US-0665350.
PR   24-OCT-2000; 2000US-242922P.
PR   08-NOV-2000; 2000US-0709238.
PR   08-NOV-2000; 2000WO-US30952.
PR   10-NOV-2000; 2000WO-US30873.
PR   01-DEC-2000; 2000WO-US32678.
PR   20-DEC-2000; 2000US-0747259.
PR   20-DEC-2000; 2000WO-US34956.
PR   22-JAN-2001; 2001US-0767609.
PR   28-FEB-2001; 2001US-0796498.
PR   28-FEB-2001; 2001WO-US06520.
PR   01-MAR-2001; 2001WO-US06666.
PR   09-MAR-2001; 2001US-0802706.
PR   14-MAR-2001; 2001US-0808689.
PR   22-MAR-2001; 2001US-0816744.
PR   05-APR-2001; 2001US-0828366.
PR   10-MAY-2001; 2001US-0854208.
PR   10-MAY-2001; 2001US-0854280.
PR   25-MAY-2001; 2001US-0866028.
PR   25-MAY-2001; 2001US-0866034.
PR   25-MAY-2001; 2001WO-US17092.
PR   30-MAY-2001; 2001US-0870574.
PR   30-MAY-2001; 2001WO-US17443.
PR   01-JUN-2001; 2001WO-US17800.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Ferrara N,  Gerber H,  Gerritsen ME,  Goddard A;
PI   Godowski PJ,  Gurney AL,  Hillan KJ,  Marsters SA,  Pan J,  Paoni NF;
PI   Stephan JF,  Watanabe CK,  Williams PM,  Wood WI,  Ye W;
XX
DR   WPI; 2002-090516/12.
DR   N-PSDB; ABL88202.
XX
PT   One hundred and eighty seven nucleic acids encoding PRO polypeptides,
```

```
PT   useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT   infarction), endothelial or angiogenic disorders in a mammal -
XX
PS   Claim 11; Fig 262; 565pp; English.
XX
CC   ABL88072 to ABL88258 encode the PRO proteins given in ABB84817 to
CC   ABB85003. The PRO proteins and polynucleotides have cardiant, cytostatic,
CC   antiangiogenic, hypotensive, vulnerary and antiarteriosclerotic
CC   activities, and can be used in gene therapy. The PRO polynucleotides,
CC   proteins, agonists and antagonists are useful for treating or diagnosing
CC   a cardiovascular, endothelial or angiogenic disorder in a mammal,
CC   e.g. cardiac hypertrophy, trauma, cancer, age-related macular
CC   degeneration, atherosclerosis, hypertension, arterial restenosis,
CC   rheumatoid arthritis, angina, myocardial infarctions, thrombophlebitis,
CC   lymphangitis, tumour angiogenesis (such as breast carcinoma and liver
CC   carcinoma) and wound healing. The PRO polynucleotides have applications
CC   in molecular biology, including use as hybridisation probes, and in
CC   chromosome and gene mapping. ABL88259 to ABL88267 represent primers and
CC   probes used in the exemplification of the present invention.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 23;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 20
ABU69682
ID   ABU69682 standard; Protein; 310 AA.
XX
AC   ABU69682;
XX
DT   05-JUN-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1868+H30.
XX
KW   Human; secreted and transmembrane protein; gene therapy; psoriasis;
KW   enterocolitis; gastrointestinal ulceration; skin disease;
KW   keratinocyte differentiation; epithelial cancer; Alzheimer's disease;
KW   squamous cell carcinoma; Parkinson's disease; inflammatory disease;
KW   amyotrophic lateral sclerosis; rheumatoid arthritis; asthma;
KW   multiple sclerosis; organ failure; atherosclerosis; cardiac injury;
KW   infertility; birth defect; premature aging; AIDS; cancer;
KW   diabetic complication; wound repair; tissue re-growth.
XX
OS   Homo sapiens.
XX
PN   US2003017463-A1.
XX
PD   23-JAN-2003.
XX
PF   11-JUL-2001; 2001US-0903640.
XX
PR   10-SEP-1998;   98WO-US18824.
PR   14-SEP-1998;   98WO-US19177.
PR   16-SEP-1998;   98WO-US19330.
PR   17-SEP-1998;   98WO-US19437.
PR   01-DEC-1998;   98WO-US25108.
PR   08-SEP-1999;   99WO-US20594.
PR   13-SEP-1999;   99WO-US20944.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   05-OCT-1999;   99WO-US23089.
PR   29-NOV-1999;   99WO-US28214.
PR   30-NOV-1999;   99WO-US28313.
PR   01-DEC-1999;   99WO-US28301.
PR   02-DEC-1999;   99WO-US28564.
PR   02-DEC-1999;   99WO-US28565.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   20-DEC-1999;   99WO-US30999.
PR   05-JAN-2000; 2000WO-US00219.
PR   11-FEB-2000; 2000WO-US03565.
PR   22-FEB-2000; 2000WO-US04414.
PR   24-FEB-2000; 2000WO-US05004.
PR   02-MAR-2000; 2000WO-US05841.
PR   20-MAR-2000; 2000WO-US07377.
PR   30-MAR-2000; 2000WO-US08439.
PR   22-MAY-2000; 2000WO-US14042.
PR   02-JUN-2000; 2000WO-US15264.
PR   28-JUL-2000; 2000WO-US20710.
PR   24-AUG-2000; 2000WO-US23328.
PR   17-SEP-1997;   97US-059113P.
PR   17-SEP-1997;   97US-059115P.
PR   17-SEP-1997;   97US-059117P.
PR   17-SEP-1997;   97US-059119P.
PR   17-SEP-1997;   97US-059121P.
PR   17-SEP-1997;   97US-059122P.
PR   17-SEP-1997;   97US-059184P.
PR   18-SEP-1997;   97US-059263P.
PR   18-SEP-1997;   97US-059266P.
PR   15-OCT-1997;   97US-062125P.
PR   17-OCT-1997;   97US-062285P.
PR   17-OCT-1997;   97US-062287P.
PR   21-OCT-1997;   97US-063486P.
PR   24-OCT-1997;   97US-062814P.
PR   24-OCT-1997;   97US-062816P.
PR   24-OCT-1997;   97US-063045P.
PR   24-OCT-1997;   97US-063120P.
PR   24-OCT-1997;   97US-063121P.
PR   24-OCT-1997;   97US-063127P.
PR   24-OCT-1997;   97US-063128P.
PR   27-OCT-1997;   97US-063327P.
PR   27-OCT-1997;   97US-063329P.
PR   28-OCT-1997;   97US-063541P.
PR   28-OCT-1997;   97US-063542P.
PR   28-OCT-1997;   97US-063544P.
PR   28-OCT-1997;   97US-063549P.
PR   28-OCT-1997;   97US-063550P.
PR   28-OCT-1997;   97US-063564P.
PR   29-OCT-1997;   97US-063435P.
PR   29-OCT-1997;   97US-063704P.
PR   29-OCT-1997;   97US-063732P.
PR   29-OCT-1997;   97US-063734P.
PR   29-OCT-1997;   97US-063735P.
PR   29-OCT-1997;   97US-063738P.
PR   29-OCT-1997;   97US-064215P.
PR   31-OCT-1997;   97US-063870P.
PR   31-OCT-1997;   97US-064103P.
PR   03-NOV-1997;   97US-064248P.
PR   07-NOV-1997;   97US-064809P.
```

```
PR   12-NOV-1997;   97US-065186P.
PR   17-NOV-1997;   97US-065846P.
PR   18-NOV-1997;   97US-065693P.
PR   21-NOV-1997;   97US-066120P.
PR   21-NOV-1997;   97US-066364P.
PR   24-NOV-1997;   97US-066453P.
PR   24-NOV-1997;   97US-066466P.
PR   24-NOV-1997;   97US-066511P.
PR   24-NOV-1997;   97US-066770P.
PR   24-NOV-1997;   97US-066772P.
PR   25-NOV-1997;   97US-066840P.
PR   12-DEC-1997;   97US-069425P.
PR   04-JUN-1998;   98US-088026P.
PR   10-SEP-1998;   98US-099803P.
PR   14-SEP-1998;   98US-100262P.
PR   17-SEP-1998;   98US-100858P.
PR   13-OCT-1998;   98US-104080P.
PR   20-NOV-1998;   98US-109304P.
PR   22-DEC-1998;   98US-113296P.
PR   07-JUL-1999;   99US-143048P.
PR   26-JUL-1999;   99US-145698P.
PR   28-JUL-1999;   99US-146222P.
PR   18-SEP-2000; 2000US-0665350.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi A,  Botstein D,  Desnoyers L,  Eaton DL,  Ferrara N;
PI   Filvaroff E,  Fong S,  Gao W,  Gerber H,  Gerritsen ME,  Goddard A;
PI   Godowski PJ,  Grimaldi JC,  Gurney AL,  Hillan KJ,  Kljavin IJ;
PI   Mather JP,  Pan J,  Paoni NF,  Roy MA,  Stewart TA,  Tumas D;
PI   Williams PM,  Wood WI;
XX
DR   WPI; 2003-341586/32.
DR   N-PSDB; ACA55169.
XX
PT   New PRO polypeptides and nucleic acid molecules, useful in diagnosing
PT   or treating inflammatory diseases, organ failure, atherosclerosis,
PT   cardiac injury, infertility, cancer, AIDS, Alzheimer's disease or
PT   Parkinson's disease -
XX
PS   Claim 12; Fig 124; 473pp; English.
XX
CC   The invention describes sixty one nucleic acids encoding PRO polypeptides
CC   (secreted and transmembrane). The PRO polypeptides and nucleic acids are
CC   useful in diagnosing or treating enterocolitis, gastrointestinal
CC   ulceration, skin diseases associated with abnormal keratinocyte
CC   differentiation, e.g. psoriasis or epithelial cancers such as squamous
CC   cell carcinoma, Alzheimer's disease, Parkinson's disease, amyotrophic
CC   lateral sclerosis, inflammatory diseases, e.g. rheumatoid arthritis,
CC   asthma or multiple sclerosis, organ failure, atherosclerosis, cardiac
CC   injury, infertility, birth defects, premature aging, AIDS, cancer,
CC   diabetic complications, or mutations in general. The polypeptides are
CC   also useful for wound repair and associated therapies concerned with
CC   re-growth of tissue. The PRO polypeptides and nucleic acid molecules
CC   are also useful in gene therapy, and as molecular weight markers for
CC   protein electrophoresis purposes. The anti-PRO antibodies may be used
CC   in diagnostic assays for PRO, or for the affinity purification of PRO
CC   from recombinant cell culture or natural sources. This is the amino
CC   acid sequence of a novel human PRO polypeptide.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 24;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 21
ABU71505
ID   ABU71505 standard; Protein; 310 AA.
XX
AC   ABU71505;
XX
DT   10-JUN-2003  (first entry)
XX
DE   Human PRO polypeptide #61.
XX
KW   Human; secreted and transmembrane protein; PRO polypeptide; cancer;
KW   Alzheimer's disease; ischaemia; cytostatic; nootropic; vasotropic;
KW   neuroprotective.
XX
OS   Homo sapiens.
XX
PN   US2002192659-A1.
XX
PD   19-DEC-2002.
XX
PF   10-JUL-2001; 2001US-0902853.
XX
PR   10-SEP-1998;   98WO-US18824.
PR   14-SEP-1998;   98WO-US19177.
PR   16-SEP-1998;   98WO-US19330.
PR   17-SEP-1998;   98WO-US19437.
PR   01-DEC-1998;   98WO-US25108.
PR   08-SEP-1999;   99WO-US20594.
PR   13-SEP-1999;   99WO-US20944.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   05-OCT-1999;   99WO-US23089.
PR   01-DEC-1999;   99WO-US28301.
PR   02-DEC-1999;   99WO-US28564.
PR   02-DEC-1999;   99WO-US28565.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   20-DEC-1999;   99WO-US30999.
PR   05-JAN-2000; 2000WO-US00219.
PR   11-FEB-2000; 2000WO-US03565.
PR   22-FEB-2000; 2000WO-US04414.
PR   28-JUL-2000; 2000WO-US20710.
PR   24-AUG-2000; 2000WO-US23328.
PR   17-SEP-1997;   97US-059113P.
PR   17-SEP-1997;   97US-059115P.
PR   17-SEP-1997;   97US-059117P.
PR   18-SEP-1997;   97US-059266P.
PR   15-OCT-1997;   97US-062125P.
PR   17-OCT-1997;   97US-062285P.
PR   17-OCT-1997;   97US-062287P.
PR   21-OCT-1997;   97US-063486P.
PR   24-OCT-1997;   97US-062814P.
PR   24-OCT-1997;   97US-062816P.
XX
PA   (GETH ) GENENTECH INC.
```

```
XX
PI   Ashkenazi A,  Botstein D,  Desnoyers L,  Eaton DL,  Ferrara N;
PI   Filvaroff E,  Fong S,  Gao W,  Gerber H,  Gerritsen ME,  Goddard A;
PI   Godowski PJ,  Grimaldi JC,  Gurney AL,  Hillan KJ,  Kljavin IJ;
PI   Mather JP,  Pan J,  Paoni NF,  Roy MA,  Stewart TA,  Tumas D;
PI   Williams PM,  Wood WI;
XX
DR   WPI; 2003-361832/34.
DR   N-PSDB; ACA58654.
XX
PT   New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO245 or
PT   PRO1868, useful in molecular biology, chromosome and gene mapping, in
PT   generating antisense RNA and DNA, and in gene therapy  -
XX
PS   Claim 12; Fig 124; 474pp; English.
XX
CC   The present invention relates to the isolation of novel human secreted
CC   and transmembrane proteins (PRO polypeptides), and the polynucleotide
CC   sequences encoding them. The polynucleotide sequences are useful in
CC   molecular biology, as hybridisation probes, in chromosome and gene
CC   mapping, in generating antisense RNA and DNA, and in gene therapy. The
CC   polynucleotide sequences may also be used in preparing PRO polypeptides
CC   by recombinant techniques, and in generating either transgenic animals
CC   or knock-out animals which, in turn, are useful in the development and
CC   screening of therapeutically useful reagents. The PRO polypeptides or
CC   their antibodies are useful in preparing a medicament for treating a
CC   condition responsive to the polypeptide or antibody, such as cancer,
CC   Alzheimer's disease or ischaemia, and in various diagnostic assays.
CC   ABU71445-ABU71505 represent human PRO polypeptides of the invention.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 24;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 22
ABU71951
ID   ABU71951 standard; Protein; 310 AA.
XX
AC   ABU71951;
XX
DT   12-JUN-2003  (first entry)
XX
DE   Human secreted/transmembrane protein PRO1868.
XX
KW   Human; secreted protein; transmembrane protein; PRO;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003003530-A1.
XX
PD   02-JAN-2003.
XX
PF   11-JUL-2001; 2001US-0904011.
XX
PR   10-SEP-1998;   98WO-US18824.
PR   14-SEP-1998;   98WO-US19177.
PR   16-SEP-1998;   98WO-US19330.
PR   17-SEP-1998;   98WO-US19437.
PR   01-DEC-1998;   98WO-US25108.
PR   08-SEP-1999;   99WO-US20594.
PR   13-SEP-1999;   99WO-US20944.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   05-OCT-1999;   99WO-US23089.
PR   29-NOV-1999;   99WO-US28214.
PR   30-NOV-1999;   99WO-US28313.
PR   01-DEC-1999;   99WO-US28301.
PR   02-DEC-1999;   99WO-US28564.
PR   02-DEC-1999;   99WO-US28565.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   20-DEC-1999;   99WO-US30999.
PR   05-JAN-2000; 2000WO-US00219.
PR   11-FEB-2000; 2000WO-US03565.
PR   22-FEB-2000; 2000WO-US04414.
PR   24-FEB-2000; 2000WO-US05004.
PR   02-MAR-2000; 2000WO-US05841.
PR   20-MAR-2000; 2000WO-US07377.
PR   30-MAR-2000; 2000WO-US08439.
PR   22-MAY-2000; 2000WO-US14042.
PR   02-JUN-2000; 2000WO-US15264.
PR   28-JUL-2000; 2000WO-US20710.
PR   24-AUG-2000; 2000WO-US23328.
PR   17-SEP-1997;   97US-059113P.
PR   17-SEP-1997;   97US-059115P.
PR   17-SEP-1997;   97US-059117P.
PR   17-SEP-1997;   97US-059119P.
PR   17-SEP-1997;   97US-059121P.
PR   17-SEP-1997;   97US-059122P.
PR   17-SEP-1997;   97US-059184P.
PR   18-SEP-1997;   97US-059263P.
PR   18-SEP-1997;   97US-059266P.
PR   15-OCT-1997;   97US-062125P.
PR   17-OCT-1997;   97US-062285P.
PR   17-OCT-1997;   97US-062287P.
PR   21-OCT-1997;   97US-063486P.
PR   24-OCT-1997;   97US-062814P.
PR   24-OCT-1997;   97US-062816P.
PR   24-OCT-1997;   97US-063045P.
PR   24-OCT-1997;   97US-063120P.
PR   24-OCT-1997;   97US-063121P.
PR   24-OCT-1997;   97US-063127P.
PR   24-OCT-1997;   97US-063128P.
PR   27-OCT-1997;   97US-063327P.
PR   27-OCT-1997;   97US-063329P.
PR   28-OCT-1997;   97US-063541P.
PR   28-OCT-1997;   97US-063542P.
PR   28-OCT-1997;   97US-063544P.
PR   28-OCT-1997;   97US-063549P.
PR   28-OCT-1997;   97US-063550P.
PR   28-OCT-1997;   97US-063564P.
PR   29-OCT-1997;   97US-063435P.
PR   29-OCT-1997;   97US-063704P.
PR   29-OCT-1997;   97US-063732P.
PR   29-OCT-1997;   97US-063734P.
PR   29-OCT-1997;   97US-063735P.
PR   29-OCT-1997;   97US-063738P.
PR   29-OCT-1997;   97US-064215P.
```

```
PR   31-OCT-1997;   97US-063870P.
PR   31-OCT-1997;   97US-064103P.
PR   03-NOV-1997;   97US-064248P.
PR   07-NOV-1997;   97US-064809P.
PR   12-NOV-1997;   97US-065186P.
PR   17-NOV-1997;   97US-065846P.
PR   18-NOV-1997;   97US-065693P.
PR   21-NOV-1997;   97US-066120P.
PR   21-NOV-1997;   97US-066364P.
PR   24-NOV-1997;   97US-066453P.
PR   24-NOV-1997;   97US-066466P.
PR   24-NOV-1997;   97US-066511P.
PR   24-NOV-1997;   97US-066770P.
PR   24-NOV-1997;   97US-066772P.
PR   18-SEP-2000; 2000US-0665350.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi A,  Botstein D,  Desnoyers L,  Eaton DL,  Ferrara N;
PI   Filvaroff E,  Fong S,  Gao W,  Gerber H,  Gerritsen ME,  Goddard A;
PI   Godowski PJ,  Grimaldi JC,  Gurney AL,  Hillan KJ,  Kljavin IJ;
PI   Mather JP,  Pan J,  Paoni NF,  Roy MA,  Stewart TA,  Tumas D;
PI   Williams PM,  Wood WI;
XX
DR   WPI; 2003-329602/31.
DR   N-PSDB; ACA60361.
XX
PT   New transmembrane polypeptides and nucleic acids encoding the
PT   polypeptides, useful in gene therapy, in chromosome identification, as
PT   chromosome markers, in generating probes and in tissue typing  -
XX
PS   Claim 12; Fig 124; 484pp; English.
XX
CC   The invention relates to an isolated nucleic acid with at least 80%
CC   nucleic acid sequence identity to a nucleotide sequence encoding one of
CC   61 secreted/transmembrane polypeptides, or PRO polypeptides or encoding a
CC   PRO protein extracellular domain. Also included are a vector comprising
CC   the PRO nucleic acid, a host cell comprising the vector, producing a PRO
CC   polypeptide (by culturing the host cell for the expression of the PRO
CC   polypeptide, and recovering the PRO polypeptide from the cell culture),
CC   an isolated PRO polypeptide (having at least 80% sequence identity
CC   to: ( a) an amino acid sequence selected from the 61 PRO proteins;
CC   (b) an amino acid sequence encoded by a nucleic acid molecule deposited
CC   with an ATCC number (detailed in the specification); or (c) an
CC   extracellular domain of a PRO polypeptide or to a PRO polypeptide lacking
CC   its associated signal peptide), a chimaeric molecule comprising a PRO
CC   polypeptide of fused to a heterologous amino acid sequence, an anti-PRO
CC   antibody, detecting a PRO245 or PRO1868 in a sample suspected of
CC   containing the polypeptide, linking a bioactive molecule to a cell
CC   expressing a PRO245 or PRO1868 and modulating at least one biological
CC   activity of a cell expressing a PRO245 or PRO1868. Nucleic acids which
CC   encode PRO can be used to generate either transgenic animals or knock-out
CC   animals which may be used in the development and screening of
CC   therapeutically useful reagents. The nucleic acids may also be used in
CC   gene therapy, in chromosome identification, as chromosome markers, or in
CC   generating probes. The PRO polypeptides are useful as molecular markers
CC   for protein electrophoresis, and the isolated nucleic acids may be used
CC   for recombinantly expressing those markers. The PRO polypeptides and
CC   nucleic acids may also be used in tissue typing. Anti-PRO antibodies
CC   are useful in diagnostic assays for PRO, and in affinity purification
CC   of PRO from recombinant cell culture or natural sources. The
CC   present sequence represents a PRO protein.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 24;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 23
ABU66838
ID   ABU66838 standard; Protein; 310 AA.
XX
AC   ABU66838;
XX
DT   23-MAY-2003  (first entry)
XX
DE   Human PRO polypeptide #269.
XX
KW   Human; PRO polypeptide; secreted and transmembrane protein;
KW   tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;
KW   differentiation; chondrocyte; tumour; genetic disorder;
KW   cytostatic.
XX
OS   Homo sapiens.
XX
PN   US2003036180-A1.
XX
PD   20-FEB-2003.
XX
PF   09-MAY-2002; 2002US-0143114.
XX
PR   31-MAR-1997;   97WO-US05230.
PR   12-JUN-1998;   98WO-US12456.
PR   14-JUL-1998;   98WO-US14552.
PR   28-AUG-1998;   98WO-US17888.
PR   10-SEP-1998;   98WO-US18824.
PR   14-SEP-1998;   98WO-US19093.
PR   14-SEP-1998;   98WO-US19094.
PR   14-SEP-1998;   98WO-US19177.
PR   16-SEP-1998;   98WO-US19330.
PR   17-SEP-1998;   98WO-US19437.
PR   07-OCT-1998;   98WO-US21141.
PR   29-OCT-1998;   98WO-US22991.
PR   29-OCT-1998;   98WO-US22992.
PR   20-NOV-1998;   98WO-US24855.
PR   01-DEC-1998;   98WO-US25108.
PR   05-JAN-1999;   99WO-US00106.
PR   08-MAR-1999;   99WO-US05028.
PR   10-MAR-1999;   99WO-US05190.
PR   20-APR-1999;   99WO-US08615.
PR   14-MAY-1999;   99WO-US10733.
PR   02-JUN-1999;   99WO-US12252.
PR   01-SEP-1999;   99WO-US20111.
PR   08-SEP-1999;   99WO-US20594.
PR   13-SEP-1999;   99WO-US20944.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   05-OCT-1999;   99WO-US23089.
PR   29-NOV-1999;   99WO-US28214.
PR   30-NOV-1999;   99WO-US28313.
```

PR 30-NOV-1999; 99WO-US28409.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 02-DEC-1999; 99WO-US28551.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 22-DEC-1999; 99WO-US30720.
PR 30-DEC-1999; 99WO-US31243.
PR 30-DEC-1999; 99WO-US31274.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05746.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 21-MAR-2000; 2000WO-US07532.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 25-MAY-2001; 2001WO-US17092.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 22-JUN-2001; 2001WO-US20116.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 20-DEC-2000; 2000US-0747259.
PR 28-FEB-2001; 2001US-0796498.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0808689.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 18-MAY-2001; 2001US-0860216.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 01-JUN-2001; 2001US-0872035.
PR 05-JUN-2001; 2001US-0874503.
PR 14-JUN-2001; 2001US-0882636.
PR 19-JUN-2001; 2001US-0886342.
PR 21-JUN-2001; 2001US-0887879.
PR 18-JUL-2001; 2001US-0908827.
PR 06-AUG-2001; 2001US-0924419.
PR 09-AUG-2001; 2001US-0927796.
PR 16-AUG-2001; 2001US-0931836.
PR 19-DEC-2001; 2001US-0028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-332040/31.
DR N-PSDB; ACA03871.
XX
PT New secreted and transmembrane PRO nucleic acids, useful for gene
PT therapy, in chromosome and gene mapping, as chromosome markers, in
PT tissue typing, and in chromosome identification -
XX
PS Claim 12; Fig 538; 660pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The
CC PRO polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for
CC linking bioactive molecules to cells expressing PRO polypeptides,
CC for modulating biological activities of cells expressing PRO
CC polypeptides, and for for identifying agonists or antagonists.
CC The PRO polypeptides are useful for for stimulating the release of
CC tumour necrosis factor (TNF)-alpha from human blood, for stimulating
CC the proliferation or differentiation of chondrocytes, and detecting the
CC presence of tumours. The polynucleotide sequences encoding PRO
CC polypeptides are useful as hybridisation probes, in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptides, for generating transgenic animals or
CC knockout animals, for the genetic analysis of individuals with genetic
CC disorders, and in gene therapy. ABU66570-ABU66844 represent the human
CC PRO polypeptides of the invention.
CC Note: The sequence data for this patent was obtained in electronic
CC format directly from the USPTO web site at
CC seqdata.uspto.gov/psipsDIDEntry.html.
XX
SQ Sequence 310 AA;

Query Match 67.4%; Score 209; DB 24; Length 310;
Best Local Similarity 99.7%; Pred. No. 1e-196;
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310
```

RESULT 24
ABU67114
ID ABU67114 standard; Protein; 310 AA.
XX
AC ABU67114;
XX
DT 27-MAY-2003 (first entry)
XX

DE Human secreted/transmembrane, PRO, protein SEQ ID 538.
XX
KW Human; secreted protein; transmembrane protein; PRO;
KW inflammatory disease; organ failure; atherosclerosis; cardiac injury;
KW infertility; birth defects; premature aging; AIDS; biosensor;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW bioreactor; tumour.
XX
OS Homo sapiens.
XX
PN US2003032155-A1.
XX
PD 13-FEB-2003.
XX
PF 03-MAY-2002; 2002US-0137865.
XX
PR 31-MAR-1997; 97WO-US05230.
PR 12-JUN-1998; 98WO-US12456.
PR 14-JUL-1998; 98WO-US14552.
PR 28-AUG-1998; 98WO-US17888.
PR 10-SEP-1998; 98WO-US18824.
PR 14-SEP-1998; 98WO-US19093.
PR 14-SEP-1998; 98WO-US19094.
PR 14-SEP-1998; 98WO-US19177.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 29-OCT-1998; 98WO-US22991.
PR 29-OCT-1998; 98WO-US22992.
PR 20-NOV-1998; 98WO-US24855.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 10-MAR-1999; 99WO-US05190.
PR 20-APR-1999; 99WO-US08615.
PR 14-MAY-1999; 99WO-US10733.
PR 02-JUN-1999; 99WO-US12252.
PR 01-SEP-1999; 99WO-US20111.
PR 08-SEP-1999; 99WO-US20594.
PR 13-SEP-1999; 99WO-US20944.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 05-OCT-1999; 99WO-US23089.
PR 29-NOV-1999; 99WO-US28214.
PR 30-NOV-1999; 99WO-US28313.
PR 30-NOV-1999; 99WO-US28409.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 02-DEC-1999; 99WO-US28551.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 22-DEC-1999; 99WO-US30720.
PR 30-DEC-1999; 99WO-US31243.
PR 30-DEC-1999; 99WO-US31274.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05746.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 21-MAR-2000; 2000WO-US07532.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 25-MAY-2001; 2001WO-US17092.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 22-JUN-2001; 2001WO-US20116.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 20-DEC-2000; 2000US-0747259.
PR 28-FEB-2001; 2001US-0796498.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0808689.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 18-MAY-2001; 2001US-0860216.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 01-JUN-2001; 2001US-0872035.
PR 05-JUN-2001; 2001US-0874503.
PR 14-JUN-2001; 2001US-0882636.
PR 19-JUN-2001; 2001US-0886342.
PR 21-JUN-2001; 2001US-0887879.
PR 18-JUL-2001; 2001US-0908827.
PR 06-AUG-2001; 2001US-0924419.
PR 09-AUG-2001; 2001US-0927796.
PR 16-AUG-2001; 2001US-0931836.
PR 19-DEC-2001; 2001US-0028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-331925/31.
DR N-PSDB; ACA04292.
XX
PT New secreted and transmembrane nucleic acids and polypeptides,
PT designated as PRO, useful for treating inflammation, organ failure,
PT atherosclerosis, cardiac injury, infertility, birth defects, premature
PT aging, AIDS, or cancer -
XX
PS Claim 12; Fig 538; 659pp; English.
XX
CC The invention relates to an isolated nucleic acid comprising, or which is
CC at least 80% identical to, or the full-length coding sequence of, any of
CC the 275 nucleotide sequences, encoding the corresponding PRO polypeptide
CC (one of 275 secreted or transmembrane proteins). The nucleic acid
CC further comprises the full-length coding sequence of the DNA deposited
CC under American Type Culture Collection (ATCC) accession number in a list
CC given in the specification. Also included are vectors and host
CC cells for producing PRO proteins, PRO fusion proteins, anti-PRO
CC antibodies, PRO extracellular domains and mature sequences, methods
CC of detecting PRO proteins, methods for stimulating the release of
CC TNF-alpha (tumour necrosis factor alpha) from human blood,
CC (and the proliferation of differentiation of chondrocyte cells, the
CC proliferation of, or gene expression in pericyte cells, the release or
CC proteoglycans from cartilage, proliferation of inner ear urticular

```
CC   supporting cells, the proliferation of T-lymphocyte cells, the release
CC   of a cytokine from peripheral blood mononuclear cells (PBMC), or the
CC   proliferation of endothelial cells), a method for modulating the uptake
CC   of glucose or free fatty acid (FFA) by skeletal muscle cells,
CC   a method for inhibiting the binding of A-peptide to factor VIIA,
CC   or the differentiation of adipocyte cells, a method for detecting the
CC   presence of a tumour in a mammal and an oligonucleotide probe derived
CC   from any of the nucleotide sequences cited above. The nucleic acids and
CC   polypeptides are useful for treating inflammatory diseases, organ
CC   failure, atherosclerosis, cardiac injury, infertility, birth defects,
CC   premature aging, AIDS (acquired immunodeficiency syndrome), cancer, or
CC   diabetic complications. The nucleic acids are useful as hybridisation
CC   probes, in chromosome and gene mapping, and in generating antisense RNA
CC   or DNA. The polypeptides are useful as pharmaceuticals, diagnostics,
CC   biosensors or bioreactors. Both are useful in tissue typing.
CC   The present sequence represents a PRO protein of the invention.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 24;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 25
ABU67405
ID   ABU67405 standard; Protein; 310 AA.
XX
AC   ABU67405;
XX
DT   29-MAY-2003  (first entry)
XX
DE   Human secreted protein PRO1868.
XX
KW   Human; gene therapy; mucosal lesion; ulcer; enterocolitis; skin disease;
KW   psoriasis; cancer; lung cancer; colon cancer; nerve cell disease;
KW   Alzheimer's disease; Parkinson's disease; Usher syndrome; angiogenesis;
KW   atrophia areata; inflammatory disease; asthma; rheumatoid arthritis;
KW   ischaemia.
XX
OS   Homo sapiens.
XX
PN   US2003023054-A1.
XX
PD   30-JAN-2003.
XX
PF   16-JUL-2001; 2001US-0906742.
XX
PR   10-SEP-1998;   98WO-US18824.
PR   14-SEP-1998;   98WO-US19177.
PR   16-SEP-1998;   98WO-US19330.
PR   17-SEP-1998;   98WO-US19437.
PR   01-DEC-1998;   98WO-US25108.
PR   08-SEP-1999;   99WO-US20594.
PR   13-SEP-1999;   99WO-US20944.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   05-OCT-1999;   99WO-US23089.
PR   29-NOV-1999;   99WO-US28214.
PR   30-NOV-1999;   99WO-US28313.
PR   01-DEC-1999;   99WO-US28301.
PR   02-DEC-1999;   99WO-US28564.
PR   02-DEC-1999;   99WO-US28565.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   20-DEC-1999;   99WO-US30999.
PR   05-JAN-2000; 2000WO-US00219.
PR   11-FEB-2000; 2000WO-US03565.
PR   22-FEB-2000; 2000WO-US04414.
PR   24-FEB-2000; 2000WO-US05004.
PR   02-MAR-2000; 2000WO-US05841.
PR   20-MAR-2000; 2000WO-US07377.
PR   30-MAR-2000; 2000WO-US08439.
PR   22-MAY-2000; 2000WO-US14042.
PR   02-JUN-2000; 2000WO-US15264.
PR   28-JUL-2000; 2000WO-US20710.
PR   24-AUG-2000; 2000WO-US23328.
PR   17-SEP-1997;   97US-059113P.
PR   17-SEP-1997;   97US-059115P.
PR   17-SEP-1997;   97US-059117P.
PR   17-SEP-1997;   97US-059119P.
PR   17-SEP-1997;   97US-059121P.
PR   17-SEP-1997;   97US-059122P.
PR   17-SEP-1997;   97US-059184P.
PR   18-SEP-1997;   97US-059263P.
PR   18-SEP-1997;   97US-059266P.
PR   15-OCT-1997;   97US-062125P.
PR   17-OCT-1997;   97US-062285P.
PR   17-OCT-1997;   97US-062287P.
PR   21-OCT-1997;   97US-063486P.
PR   24-OCT-1997;   97US-062814P.
PR   24-OCT-1997;   97US-062816P.
PR   24-OCT-1997;   97US-063045P.
PR   24-OCT-1997;   97US-063120P.
PR   24-OCT-1997;   97US-063121P.
PR   24-OCT-1997;   97US-063127P.
PR   24-OCT-1997;   97US-063128P.
PR   27-OCT-1997;   97US-063327P.
PR   27-OCT-1997;   97US-063329P.
PR   28-OCT-1997;   97US-063541P.
PR   28-OCT-1997;   97US-063542P.
PR   28-OCT-1997;   97US-063544P.
PR   28-OCT-1997;   97US-063549P.
PR   28-OCT-1997;   97US-063550P.
PR   28-OCT-1997;   97US-063564P.
PR   29-OCT-1997;   97US-063435P.
PR   29-OCT-1997;   97US-063704P.
PR   29-OCT-1997;   97US-063732P.
PR   29-OCT-1997;   97US-063734P.
PR   29-OCT-1997;   97US-063735P.
PR   29-OCT-1997;   97US-063738P.
PR   29-OCT-1997;   97US-064215P.
PR   31-OCT-1997;   97US-063870P.
PR   31-OCT-1997;   97US-064103P.
PR   03-NOV-1997;   97US-064248P.
PR   07-NOV-1997;   97US-064809P.
PR   12-NOV-1997;   97US-065186P.
PR   17-NOV-1997;   97US-065846P.
PR   18-NOV-1997;   97US-065693P.
PR   21-NOV-1997;   97US-066120P.
PR   21-NOV-1997;   97US-066364P.
PR   24-NOV-1997;   97US-066453P.
```

```
PR   24-NOV-1997;   97US-066466P.
PR   24-NOV-1997;   97US-066511P.
PR   24-NOV-1997;   97US-066770P.
PR   24-NOV-1997;   97US-066772P.
PR   25-NOV-1997;   97US-066840P.
PR   12-DEC-1997;   97US-069425P.
PR   04-JUN-1998;   98US-088026P.
PR   10-SEP-1998;   98US-099803P.
PR   14-SEP-1998;   98US-100262P.
PR   17-SEP-1998;   98US-100858P.
PR   13-OCT-1998;   98US-104080P.
PR   20-NOV-1998;   98US-109304P.
PR   22-DEC-1998;   98US-113296P.
PR   07-JUL-1999;   99US-143048P.
PR   26-JUL-1999;   99US-145698P.
PR   28-JUL-1999;   99US-146222P.
PR   18-SEP-2000; 2000US-0665350.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi A,  Botstein D,  Desnoyers L,  Eaton DL,  Ferrara N;
PI   Filvaroff E,  Fong S,  Gao W,  Gerber H,  Gerritsen ME,  Goddard A;
PI   Godowski PJ,  Grimaldi JC,  Gurney AL,  Hillan KJ,  Kljavin IJ;
PI   Mather JP,  Pan J,  Paoni NF,  Roy MA,  Stewart TA,  Tumas D;
PI   Williams PM,  Wood WI;
XX
DR   WPI; 2003-331485/31.
DR   N-PSDB; ACA05699.
XX
PT   Sixty one isolated nucleic acids encoding a PRO polypeptide, e.g.
PT   PRO245 or PRO1868, useful in chromosome and gene mapping, in generating
PT   antisense RNA and DNA, and in treating cancer and Alzheimer's disease -
XX
PS   Disclosure; Fig 124; 481pp; English.
XX
CC   The invention relates to sixty one nucleic acids encoding PRO
CC   polypeptides (secreted and transmembrane). The polynucleotide is useful
CC   in molecular biology, including uses as hybridisation probes, in
CC   chromosome and gene mapping, in generating antisense RNA and DNA, and in
CC   gene therapy. The polynucleotide may also be used in preparing PRO
CC   polypeptides by recombinant techniques, and in generating either
CC   transgenic animals or knock-out animals which, in turn, are useful in the
CC   development and screening of therapeutically useful reagents. The PRO
CC   polypeptide or the antibody is used in preparing a medicament for
CC   treating a condition responsive to the polypeptide or antibody, such as
CC   mucosal lesions e.g. ulcers and enterocolitis, skin disease e.g.
CC   psoriasis, cancer e.g. lung cancer and colon cancer, nerve cell disease
CC   e.g. Alzheimer's disease and Parkinson's disease, Usher syndrome,
CC   atrophia areata, angiogenesis, inflammatory disease e.g asthma and
CC   rheumatoid arthritis, ischaemia, and in various diagnostic assays. The
CC   present sequence represents the amino acid sequence of a PRO polypeptide.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 24;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 26
ABU59919
ID   ABU59919 standard; Protein; 310 AA.
XX
AC   ABU59919;
XX
DT   13-MAY-2003  (first entry)
XX
DE   Novel secreted and transmembrane protein PRO1868.
XX
KW   Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW   cardiac insufficiency disorder; cancer; tumour; immune response;
KW   adrenal cortical capillary endothelial growth; c-fos induction;
KW   vascular endothelial growth factor inhibition; VEGF inhibition;
KW   endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW   retinal neurons cell survival; rod photoreceptor cell survival;
KW   retinal disorder; retinitis pigmentosum; kidney disorder;
KW   mammalian kidney mesangial cell proliferation; Berger disease;
KW   dermatitis; herpetiformis; Crohn's disease; chondrocyte proliferation;
KW   chondrocyte redifferentiation; sports injury; arthritis.
XX
OS   Homo sapiens.
XX
PN   US2003017563-A1.
XX
PD   23-JAN-2003.
XX
PF   07-MAY-2002; 2002US-0140808.
XX
PR   31-MAR-1997;   97WO-US05230.
PR   12-JUN-1998;   98WO-US12456.
PR   14-JUL-1998;   98WO-US14552.
PR   28-AUG-1998;   98WO-US17888.
PR   10-SEP-1998;   98WO-US18824.
PR   14-SEP-1998;   98WO-US19093.
PR   14-SEP-1998;   98WO-US19094.
PR   14-SEP-1998;   98WO-US19177.
PR   16-SEP-1998;   98WO-US19330.
PR   17-SEP-1998;   98WO-US19437.
PR   07-OCT-1998;   98WO-US21141.
PR   29-OCT-1998;   98WO-US22991.
PR   29-OCT-1998;   98WO-US22992.
PR   20-NOV-1998;   98WO-US24855.
PR   01-DEC-1998;   98WO-US25108.
PR   05-JAN-1999;   99WO-US00106.
PR   08-MAR-1999;   99WO-US05028.
PR   10-MAR-1999;   99WO-US05190.
PR   20-APR-1999;   99WO-US08615.
PR   14-MAY-1999;   99WO-US10733.
PR   02-JUN-1999;   99WO-US12252.
PR   01-SEP-1999;   99WO-US20111.
PR   08-SEP-1999;   99WO-US20594.
PR   13-SEP-1999;   99WO-US20944.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   05-OCT-1999;   99WO-US23089.
PR   29-NOV-1999;   99WO-US28214.
PR   30-NOV-1999;   99WO-US28313.
PR   30-NOV-1999;   99WO-US28409.
PR   01-DEC-1999;   99WO-US28301.
PR   01-DEC-1999;   99WO-US28634.
PR   02-DEC-1999;   99WO-US28551.
PR   02-DEC-1999;   99WO-US28564.
```

PR 02-DEC-1999; 99WO-US28565.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 22-DEC-1999; 99WO-US30720.
PR 30-DEC-1999; 99WO-US31243.
PR 30-DEC-1999; 99WO-US31274.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05746.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 21-MAR-2000; 2000WO-US07532.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 25-MAY-2001; 2001WO-US17092.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 22-JUN-2001; 2001WO-US20116.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 20-DEC-2000; 2000US-0747259.
PR 28-FEB-2001; 2001US-0796498.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0808689.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 18-MAY-2001; 2001US-0860216.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 01-JUN-2001; 2001US-0872035.
PR 05-JUN-2001; 2001US-0874503.
PR 14-JUN-2001; 2001US-0882636.
PR 19-JUN-2001; 2001US-0886342.
PR 21-JUN-2001; 2001US-0887879.
PR 18-JUL-2001; 2001US-0908827.
PR 06-AUG-2001; 2001US-0924419.
PR 09-AUG-2001; 2001US-0927796.
PR 16-AUG-2001; 2001US-0931836.
PR 19-DEC-2001; 2001US-0028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-148238/14.
DR N-PSDB; ABX89409.
XX
PT Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
PT are therapeutically useful for enhancing immune response and in cancer
PT treatments -
XX
PS Claim 12; Fig 538; 659pp; English.
XX
CC The invention describes an isolated human PRO polypeptide. The PRO
CC polypeptides are useful in detecting PRO polypeptides in a sample, in
CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and
CC in modulating at least one biological activity of a cell expressing a PRO
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
CC stimulate adrenal cortical capillary endothelial growth, and PRO536,
CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
CC useful for treating conditions or disorders where angiogenesis would be
CC beneficial, e.g. wound healing and antagonist of this polypeptide are
CC useful for treating cancerous tumours. PRO812 inhibits vascular
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial
CC cells and is thus useful for inhibiting endothelial cell growth in
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
CC stimulated T-lymphocytes and are therapeutically useful for enhancing
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
CC rod photoreceptor cells) and therefore are useful for treating retinal
CC disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813
CC and PRO11066 induce proliferation of mammalian kidney mesangial cells,
CC and therefore are useful for treating kidney disorders associated with
CC decreased mesangial cell function such as Berger disease or other
CC nephropathies associated with dermatitis, herpetiformis or Crohn's
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
CC proliferation and/or redifferentiation of chondrocytes in culture and
CC are thus useful for treating sports injuries, and arthritis. This
CC is the amino acid sequence of a novel human PRO protein.
XX
SQ Sequence 310 AA;

Query Match 67.4%; Score 209; DB 24; Length 310;
Best Local Similarity 99.7%; Pred. No. 1e-196;
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310
```

RESULT 27
ABU60813
ID ABU60813 standard; Protein; 310 AA.

XX
AC ABU60813;
XX
DT 06-MAY-2003 (first entry)
XX
DE Human secreted/transmembrane protein, #7.
XX
KW Human; PRO; secreted; transmembrane; pharmaceutical;
KW diagnostic; biosensor; bioreactor; therapeutic; gene therapy; tumour;
KW inflammatory disease; immune-related disease; inflammatory bowel disease;
KW IBD; systemic lupus erythematosus; rheumatoid arthritis; thyroiditis;
KW diabetes mellitus; glomerulonephritis; multiple sclerosis; cirrhosis;
KW psoriasis; graft rejection; antiinflammatory; immunosuppressive;
KW neuroprotective; hepatotropic.
XX
OS Homo sapiens.
XX
PN US2002160392-A1.
XX
PD 31-OCT-2002.
XX
PF 27-DEC-2001; 2001US-0033245.
XX
PR 02-JUN-1999; 99WO-US12252.
PR 01-DEC-1999; 99WO-US28634.
PR 02-DEC-1999; 99WO-US28551.
PR 11-FEB-2000; 2000WO-US03565.
PR 22-FEB-2000; 2000WO-US04414.
PR 02-MAR-2000; 2000WO-US05841.
PR 30-MAR-2000; 2000WO-US08439.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 01-DEC-2000; 2000WO-US32678.
PR 04-AUG-1998; 98US-095325P.
PR 16-DEC-1998; 98US-112851P.
PR 16-DEC-1998; 98US-113145P.
PR 22-DEC-1998; 98US-113511P.
PR 12-JAN-1999; 99US-115558P.
PR 12-JAN-1999; 99US-115565P.
PR 12-JAN-1999; 99US-115733P.
PR 09-FEB-1999; 99US-119341P.
PR 10-FEB-1999; 99US-119537P.
PR 12-FEB-1999; 99US-119965P.
PR 29-OCT-1999; 99US-162506P.
PR 09-DEC-1999; 99US-170262P.
PR 03-MAR-2000; 2000US-187202P.
PR 25-MAY-2001; 2001US-0866034.
XX
PA (GETH) GENENTECH INC.
XX
PI Botstein D, Desnoyers L, Ferrara N, Fong S, Gao W, Goddard A;
PI Gurney AL, Pan J, Roy MA, Stewart TA, Tumas D, Watanabe CK;
PI Wood WI;
XX
DR WPI; 2003-275292/27.
DR N-PSDB; ABX90609.
XX
PT New isolated PRO polypeptide, e.g. PRO1800 or PRO539, useful for
PT diagnosing, preventing and treating tumors and inflammatory or
PT immune-related diseases, e.g. systemic lupus erythematosus,
PT thyroiditis, diabetes or psoriasis -
XX
PS Claim 12; Fig 14; 119pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC comprising a sequence without signal peptide and the nucleic acid
CC encoding them. The polypeptides can be used to raise antibodies that
CC specifically bind to the PRO polypeptide, for linking a bioactive
CC molecule to a cell expressing a PRO protein and for modulating at least
CC one biological activity of a cell. The PRO polypeptides and the antibody
CC are useful for diagnosing, preventing and treating tumours and
CC inflammatory or immune-related diseases, such as inflammatory bowel
CC disease (IBD), systemic lupus erythematosus, rheumatoid arthritis,
CC thyroiditis, diabetes mellitus, glomerulonephritis, multiple sclerosis,
CC cirrhosis, psoriasis or graft rejection. The proteins and the antibody
CC may also be used in preparing medicines and medicaments for treating the
CC above-mentioned diseases. The polynucleotide is useful in molecular
CC biology, including uses as hybridisation probes, in chromosome and gene
CC mapping, in generating antisense RNA and DNA, and in gene therapy. The
CC polynucleotide may also be used in preparing PRO polypeptides by
CC recombinant techniques, and in generating either transgenic animals or
CC knock-out animals which, in turn, are useful in the development and
CC screening of therapeutically useful reagents. The sequences presented in
CC ABU60807-ABU60815 are the human PRO polynucleotides of the invention.
XX
SQ Sequence 310 AA;

Query Match 67.4%; Score 209; DB 24; Length 310;
Best Local Similarity 99.7%; Pred. No. 1e-196;
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60.

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310
```

RESULT 28
ABU64559
ID ABU64559 standard; Protein; 310 AA.
XX
AC ABU64559;
XX
DT 13-MAY-2003 (first entry)
XX
DE Human secreted/transmembrane protein, #63.
XX
KW Human; PRO; secreted; transmembrane; pharmaceutical;
KW diagnostic; biosensor; bioreactor; therapeutic; hyperplasia;
KW endometriosis; cancer; tumour; ischaemia; coronary arterial disease;
KW polycystic kidney disease; renal failure; inflammatory response; asthma;
KW rheumatoid arthritis; psoriasis; multiple sclerosis; gene therapy;
KW cytostatic; gynecological; cardiant; nephrotropic; hepatotropic;
KW antiinflammatory.
XX
OS Homo sapiens.
XX
PN US2002160374-A1.
XX
PD 31-OCT-2002.
XX
PF 12-JUL-2001; 2001US-0905291.
XX
PR 10-SEP-1998; 98WO-US18824.
PR 14-SEP-1998; 98WO-US19177.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.

PR 01-DEC-1998; 98WO-US25108.
PR 08-SEP-1999; 99WO-US20594.
PR 13-SEP-1999; 99WO-US20944.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 05-OCT-1999; 99WO-US23089.
PR 29-NOV-1999; 99WO-US28214.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 05-JAN-2000; 2000WO-US00219.
PR 11-FEB-2000; 2000WO-US03565.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 22-MAY-2000; 2000WO-US14042.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 24-AUG-2000; 2000WO-US23328.
PR 17-SEP-1997; 97US-059113P.
PR 17-SEP-1997; 97US-059115P.
PR 17-SEP-1997; 97US-059117P.
PR 17-SEP-1997; 97US-059119P.
PR 17-SEP-1997; 97US-059121P.
PR 17-SEP-1997; 97US-059122P.
PR 17-SEP-1997; 97US-059184P.
PR 18-SEP-1997; 97US-059263P.
PR 18-SEP-1997; 97US-059266P.
PR 15-OCT-1997; 97US-062125P.
PR 17-OCT-1997; 97US-062285P.
PR 17-OCT-1997; 97US-062287P.
PR 21-OCT-1997; 97US-063486P.
PR 24-OCT-1997; 97US-062814P.
PR 24-OCT-1997; 97US-062816P.
PR 24-OCT-1997; 97US-063045P.
PR 24-OCT-1997; 97US-063120P.
PR 24-OCT-1997; 97US-063121P.
PR 24-OCT-1997; 97US-063127P.
PR 24-OCT-1997; 97US-063128P.
PR 27-OCT-1997; 97US-063327P.
PR 27-OCT-1997; 97US-063329P.
PR 28-OCT-1997; 97US-063541P.
PR 28-OCT-1997; 97US-063542P.
PR 28-OCT-1997; 97US-063544P.
PR 28-OCT-1997; 97US-063549P.
PR 28-OCT-1997; 97US-063550P.
PR 28-OCT-1997; 97US-063564P.
PR 29-OCT-1997; 97US-063435P.
PR 29-OCT-1997; 97US-063704P.
PR 29-OCT-1997; 97US-063732P.
PR 29-OCT-1997; 97US-063734P.
PR 29-OCT-1997; 97US-063735P.
PR 29-OCT-1997; 97US-063738P.
PR 29-OCT-1997; 97US-064215P.
PR 31-OCT-1997; 97US-063870P.
PR 31-OCT-1997; 97US-064103P.
PR 03-NOV-1997; 97US-064248P.
PR 07-NOV-1997; 97US-064809P.
PR 12-NOV-1997; 97US-065186P.
PR 17-NOV-1997; 97US-065846P.
PR 18-NOV-1997; 97US-065693P.
PR 21-NOV-1997; 97US-066120P.
PR 21-NOV-1997; 97US-066364P.
PR 24-NOV-1997; 97US-066453P.
PR 24-NOV-1997; 97US-066466P.
PR 24-NOV-1997; 97US-066511P.
PR 24-NOV-1997; 97US-066770P.
PR 24-NOV-1997; 97US-066772P.
PR 18-SEP-2000; 2000US-0665350.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
DR WPI; 2003-288105/28.
DR N-PSDB; ABX96378.
XX
PT New secreted and transmembrane PRO polypeptides (e.g. PRO533 or PRO245)
PT and genes encoding them, useful for detecting or treating e.g.
PT hyperplasia, endometriosis, cancers, ischemia, coronary arterial
PT disease or inflammations -
XX
PS Claim 12; Fig 124; 477pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to
CC raise antibodies that specifically bind to the PRO polypeptide, for
CC linking a bioactive molecule to a cell expressing a PRO protein and for
CC modulating at least one biological activity of a cell. The PRO
CC polypeptides or polynucleotides are also useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors, for detecting or treating e.g.
CC hyperplasia, endometriosis, cancers (e.g. those involving solid tumours),
CC ischaemia, coronary arterial disease, polycystic kidney disease, chronic
CC or acute renal failure, or inflammatory responses (e.g. asthma,
CC rheumatoid arthritis, psoriasis or multiple sclerosis) in mammals. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequences presented in ABU64499-ABU64559 are the
CC PRO polynucleotides of the invention.
XX
SQ Sequence 310 AA;

Query Match 67.4%; Score 209; DB 24; Length 310;
Best Local Similarity 99.7%; Pred. No. 1e-196;
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310
```

RESULT 29
ABG73314
ID ABG73314 standard; Protein; 310 AA.
XX
AC ABG73314;
XX

DT 30-APR-2003 (first entry)
XX
DE Human PRO1868 polypeptide.
XX
KW Human; secreted and transmembrane polypeptide; PRO polypeptide;
KW inflammatory disease; immune-related disease; diabetes mellitus;
KW rheumatoid arthritis; glomerulonephritis; multiple sclerosis;
KW immune-mediated skin disease; contact dermatitis; graft rejection;
KW transplantation associated disease; graft-versus-host disease;
KW tumour diagnosis; tumour cell; antiinflammatory; immunosuppressive;
KW cytostatic; antianaemic; antirheumatic; antiarthritic; antithyroid;
KW antidiabetic; nephrotropic; antipsoriatic; dermatological; haemostatic;
KW hepatotropic; virucide; neuroprotective; PRO1868.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..30
FT /label= Signal_peptide
FT Protein 31..310
FT /label= Mature_PRO1868_polypeptide
XX
PN US2002164646-A1.
XX
PD 07-NOV-2002.
XX
PF 27-DEC-2001; 2001US-0033223.
XX
PR 02-JUN-1999; 99WO-US12252.
PR 01-DEC-1999; 99WO-US28634.
PR 02-DEC-1999; 99WO-US28551.
PR 11-FEB-2000; 2000WO-US03565.
PR 22-FEB-2000; 2000WO-US04414.
PR 02-MAR-2000; 2000WO-US05841.
PR 30-MAR-2000; 2000WO-US08439.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 01-DEC-2000; 2000WO-US32678.
PR 16-DEC-1998; 98US-113145P.
PR 22-DEC-1998; 98US-113511P.
PR 12-JAN-1999; 99US-115558P.
PR 12-JAN-1999; 99US-115565P.
PR 12-JAN-1999; 99US-115733P.
PR 09-FEB-1999; 99US-119341P.
PR 10-FEB-1999; 99US-119537P.
PR 12-FEB-1999; 99US-119965P.
PR 29-OCT-1999; 99US-162506P.
XX
PA (GETH) GENENTECH INC.
XX
PI Botstein D, Desnoyers L, Ferrara N, Fong S, Gao W, Goddard A;
PI Gurney AL, Pan J, Roy MA, Stewart TA, Tumas D, Watanabe CK;
PI Wood WI;
XX
DR WPI; 2003-238305/23.
DR N-PSDB; ABX11173.
XX
PT New PRO polypeptides and nucleic acid molecules, useful in diagnosing
PT or treating inflammatory diseases or immune-related diseases, e.g.
PT inflammatory bowel disease, systemic lupus erythematosus or rheumatoid
PT arthritis -
XX
PS Claim 12; Fig 14; 119pp; English.
XX
CC The present invention relates to the isolation of novel human
CC secreted and transmembrane polypeptides designated PRO polypeptides
CC (PRO1800, PRO539, PRO982, PRO1434, PRO1863, PRO1917, PRO1868, PRO3434
CC and PRO1927), and the polynucleotide sequences encoding them. The PRO
CC polypeptides and polynucleotide sequences of the invention are useful
CC in diagnosing or treating inflammatory diseases or immune-related
CC diseases (e.g. inflammatory bowel disease, systemic lupus
CC erythematosus, rheumatoid arthritis, Sjogren's syndrome, autoimmune
CC haemolytic anaemia, autoimmune thrombocytopaenia, thyroiditis, diabetes
CC mellitus, glomerulonephritis, multiple sclerosis, infectious hepatitis,
CC immune-mediated skin diseases including psoriasis or contact dermatitis,
CC and transplantation associated diseases including graft rejection or
CC graft-versus-host disease). The PRO polypeptides are also useful for
CC diagnosing tumours, and for inhibiting the growth of tumour cells. The
CC PRO polynucleotide sequences may be used as hybridisation probes in
CC chromosome and gene mapping, and in generating antisense RNA and DNA.
CC They are also useful in preparing PRO polypeptides, in assays to
CC identify other proteins or molecules involved in a binding reaction,
CC to generate transgenic animals or knockout animals, which in turn are
CC useful in the development and screening of therapeutically useful
CC reagents, for chromosome identification, and tissue typing. The PRO
CC polynucleotide sequences are also useful in gene therapy. Anti-PRO
CC antibodies may be used in diagnostic assays for PRO polypeptides.
CC The present sequence represents human PRO1868 polypeptide.
XX
SQ Sequence 310 AA;

Query Match 67.4%; Score 209; DB 24; Length 310;
Best Local Similarity 99.7%; Pred. No. 1e-196;
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310
```

RESULT 30
ABP71277
ID ABP71277 standard; Protein; 310 AA.
XX
AC ABP71277;
XX
DT 28-APR-2003 (first entry)
XX
DE Human junctional adhesion molecule 3 (JAM3).
XX
KW Junctional adhesion molecule; JAM3; JAM2; antiasthmatic; antirheumatic;
KW antiarthritic; antithyroid; immunosuppressive; thyromimetic; virucide;
KW hepatotropic; antiinflammatory; antidiabetic; haemostatic; antipsoriatic;
KW antiallergic; human; chromosome 11q25.
XX
OS Homo sapiens.
XX
PN WO2003006673-A2.
XX
PD 23-JAN-2003.
XX
PF 10-JUL-2002; 2002WO-US21697.
XX
PR 11-JUL-2001; 2001US-304603P.
XX
PA (TEXA-) TEXAS BIOTECHNOLOGY CORP.

```
XX
PI   Cunningham S;
XX
DR   WPI; 2003-210431/20.
DR   N-PSDB; ABZ58894.
XX
PT   Identifying compounds that bind to junctional adhesion molecules (JAM3
PT   or JAM2) or modulators of binding between JAM and other molecules for
PT   treating or alleviating e.g. arthritis, hepatitis, Crohn's disease or
PT   graft rejection -
XX
PS   Examples; Page 85-86; 90pp; English.
XX
CC   The invention relates to identifying compounds that bind to junctional
CC   adhesion molecule 3 (JAM3), JAM2, or modulators of binding between JAM3,
CC   JAM2 and other junctional adhesion molecules by detecting binding between
CC   JAM3 and a test compound, or detecting binding between JAM3 and other
CC   molecules. The identified compounds or modulators may be employed for
CC   treating or alleviating e.g. arthritis, asthma, rheumatoid arthritis,
CC   systemic lupus erythematosus, thrombocytopenia, Grave's disease,
CC   Hashimoto's thyroiditis, hepatitis, diabetes mellitus, Crohn's disease,
CC   psoriasis, allergic rhinitis, idiopathic pulmonary fibrosis, graft
CC   rejection or graft-versus-host disease. The present sequence represents
CC   the human JAM3 polypeptide.
XX
SQ   Sequence   310 AA;

  Query Match          67.4%;  Score 209;  DB 24;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 31
ABU54407
ID   ABU54407 standard; Protein; 310 AA.
XX
AC   ABU54407;
XX
DT   10-MAR-2003  (first entry)
XX
DE   Human secreted/transmembrane protein PRO1868.
XX
KW   Human; PRO; secreted protein; transmembrane protein; enterocolitis;
KW   gastrointestinal ulceration; skin disease;
KW   abnormal keratinocyte differentiation; psoriasis; epithelial cancer;
KW   squamous cell carcinoma; Alzheimer's disease; Parkinson's disease;
KW   amyotrophic lateral sclerosis; inflammatory disease;
KW   rheumatoid arthritis; asthma; multiple sclerosis; organ failure;
KW   atherosclerosis; cardiac injury; infertility; birth defect;
KW   premature aging; AIDS; acquired immunodeficiency syndrome; cancer;
KW   diabetic complication; wound repair.
XX
OS   Homo sapiens.
XX
PN   US2002132240-A1.
XX
PD   19-SEP-2002.
XX
PF   18-JUL-2001; 2001US-0909320.
XX
PR   10-SEP-1998;   98WO-US18824.
PR   14-SEP-1998;   98WO-US19177.
PR   16-SEP-1998;   98WO-US19330.
PR   17-SEP-1998;   98WO-US19437.
PR   01-DEC-1998;   98WO-US25108.
PR   08-SEP-1999;   99WO-US20594.
PR   13-SEP-1999;   99WO-US20944.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   05-OCT-1999;   99WO-US23089.
PR   01-DEC-1999;   99WO-US28301.
PR   02-DEC-1999;   99WO-US28564.
PR   02-DEC-1999;   99WO-US28565.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   20-DEC-1999;   99WO-US30999.
PR   06-JAN-2000; 2000WO-US00219.
PR   11-FEB-2000; 2000WO-US03565.
PR   22-FEB-2000; 2000WO-US04414.
PR   28-JUL-2000; 2000WO-US20710.
PR   24-AUG-2000; 2000WO-US23328.
PR   17-SEP-1997;   97US-059113P.
PR   17-SEP-1997;   97US-059115P.
PR   17-SEP-1997;   97US-059117P.
PR   15-OCT-1997;   97US-062125P.
PR   17-OCT-1997;   97US-062285P.
PR   17-OCT-1997;   97US-062287P.
PR   21-OCT-1997;   97US-063486P.
PR   24-OCT-1997;   97US-062814P.
PR   24-OCT-1997;   97US-062816P.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi A,  Botstein D,  Desnoyers L,  Eaton DL,  Ferrara N;
PI   Filvaroff E,  Fong S,  Gao W,  Gerber H,  Gerritsen ME,  Goddard A;
PI   Godowski PJ,  Grimaldi JC,  Gurney AL,  Hillan KJ,  Kljavin IJ;
PI   Mather JP,  Pan J,  Paoni NF,  Roy MA,  Stewart TA,  Tumas D;
PI   Williams PM,  Wood WI;
XX
DR   WPI; 2003-147434/14.
DR   N-PSDB; ABX71810.
XX
PT   New PRO polypeptides and nucleic acid molecules, useful in diagnosing
PT   or treating inflammatory diseases, organ failure, atherosclerosis,
PT   cardiac injury, infertility, cancer, AIDS, Alzheimer's disease or
PT   Parkinson's disease -
XX
PS   Claim 12; Fig 124; 473pp; English.
XX
CC   The invention relates to an isolated PRO polypeptide having at least 80%
CC   amino acid sequence identity to: (a) any one of 61 fully defined amino
CC   acid sequences given in the specification (appearing as ABU54347-
CC   ABU54407); (b) an amino acid sequence encoded by the nucleotide sequence
CC   deposited under American Type Culture Collection (accession numbers
CC   listed in the specification); (c) any one of the PRO sequences which
CC   lacks its associated signal peptide; (d) an extracellular domain of the
CC   PRO polypeptide with its associated signal peptide; or (e) an
CC   extracellular domain of the PRO polypeptide which lacks its associated
CC   signal peptide. Also include are the nucleic acids encoding the PRO
CC   polypeptides, vectors, host cells and anti-PRO antibodies.
CC   The PRO polypeptides and nucleic acids are useful in diagnosing
CC   or treating enterocolitis, gastrointestinal ulceration, skin diseases
```

```
CC   associated with abnormal keratinocyte differentiation, e.g. psoriasis
CC   or epithelial cancers such as squamous cell carcinoma, Alzheimer's
CC   disease, Parkinson's disease, amyotrophic lateral sclerosis,
CC   inflammatory diseases, e.g. rheumatoid arthritis, asthma or multiple
CC   sclerosis, organ failure, atherosclerosis, cardiac injury, infertility,
CC   birth defects, premature aging, AIDS, cancer, diabetic complications,
CC   or mutations in general. The polypeptides are also useful for wound
CC   repair and associated therapies concerned with re-growth of tissue. The
CC   nucleotide sequences may be used as hybridisation probes in chromosome
CC   and gene mapping, or in generating antisense RNA and DNA. PRO nucleic
CC   acids are also useful in preparing PRO polypeptides, in assays to
CC   identify other proteins or molecules involved in binding reaction, to
CC   generate transgenic animals or knockout animals, which in turn are
CC   useful in the development and screening of therapeutically useful
CC   reagents, for chromosome identification, and tissue typing. The PRO
CC   polypeptides and nucleic acid molecules are also useful in gene
CC   therapy, and as molecular weight markers for protein electrophoresis
CC   purposes. The anti-PRO antibodies may be used in diagnostic assays for
CC   PRO, or for the affinity purification of PRO from recombinant cell
CC   culture or natural sources. The present sequence represents a PRO
CC   polypeptide.
XX
SQ   Sequence   310 AA;

  Query Match             67.4%;  Score 209;  DB 24;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 32
AAB38333
ID   AAB38333 standard; Protein; 311 AA.
XX
AC   AAB38333;
XX
DT   31-JAN-2001  (first entry)
XX
DE   Human secreted protein encoded by gene 13 clone HAPSA79.
XX
KW   Immunosuppressive; antiarthritic; antirheumatic; antiproliferative;
KW   cytostatic; cardiant; vasotropic; cerebroprotective; neuroprotective;
KW   nootropic; antibacterial; virucide; fungicide; opthalmalogical; human;
KW   vulnerary; gene therapy; infection; secreted protein.
XX
OS   Homo sapiens.
XX
PN   WO200061623-A1.
XX
PD   19-OCT-2000.
XX
PF   06-APR-2000; 2000WO-US08979.
XX
PR   09-APR-1999;   99US-0128693.
PR   26-APR-1999;   99US-0130991.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Ni J,  Komatsoulis GA,  Rosen CA,  Soppet DR,  Shi Y;
PI   Lafleur DW,  Olsen HS,  Ebner R,  Florence KA,  Moore PA,  Birse CE;
PI   Young PE;
XX
DR   WPI; 2000-647418/62.
XX
PT   New nucleic acid molecules encoding 62 human secreted proteins for
PT   diagnosing, preventing, treating or ameliorating medical conditions and
PT   used as food additives or preservatives -
XX
PS   Claim 11; Page 603-604; 716pp; English.
XX
CC   Sequences AAB38321-B38396 represent the amino acid sequences of 62
CC   human secreted proteins encoded by the genes AAC69512-C69587. The genes
CC   and proteins are useful for preventing, ameliorating or treating medical
CC   conditions, e.g. by protein or gene therapy. The genes are isolated from
CC   a range of human tissues disclosed in the specification. The nucleic
CC   acids, proteins, antibodies and (ant)agonists are useful in the
CC   diagnosis, treatment and prevention of: (a) autoimmune diseases e.g.
CC   rheumatoid arthritis; (b) hyperproliferative disorders e.g. neoplasms
CC   of the breast or liver; (c) cardiovascular disorders e.g. cardiac
CC   arrest; (d) cerebrovascular disorders e.g. cerebral ischemia; (e)
CC   angiogenesis; (f) nervous system disorders e.g. Alzheimer's disease; (g)
CC   infections caused by bacteria, viruses and fungi; and (h) ocular
CC   disorders e.g. corneal infection. The polypeptides can also be used to
CC   aid wound healing and epithelial cell proliferation, to prevent skin
CC   aging due to sunburn, to maintain organs before transplantation, for
CC   supporting cell culture of primary tissues, to regenerate tissues and in
CC   chemotaxis.
XX
SQ   Sequence   311 AA;

  Query Match             67.4%;  Score 209;  DB 21;  Length 311;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 33
AAB38383
ID   AAB38383 standard; Protein; 311 AA.
XX
```

```
AC   AAB38383;
XX
DT   31-JAN-2001  (first entry)
XX
DE   Human secreted protein encoded by gene 13 clone HAPSA79.
XX
KW   Immunosuppressive; antiarthritic; antirheumatic; antiproliferative;
KW   cytostatic; cardiant; vasotropic; cerebroprotective; neuroprotective;
KW   nootropic; antibacterial; virucide; fungicide; opthalmalogical; human;
KW   vulnerary; gene therapy; infection; secreted protein.
XX
OS   Homo sapiens.
XX
PN   WO200061623-A1.
XX
PD   19-OCT-2000.
XX
PF   06-APR-2000; 2000WO-US08979.
XX
PR   09-APR-1999;   99US-0128693.
PR   26-APR-1999;   99US-0130991.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Ni J,  Komatsoulis GA,  Rosen CA,  Soppet DR,  Shi Y;
PI   Lafleur DW,  Olsen HS,  Ebner R,  Florence KA,  Moore PA,  Birse CE;
PI   Young PE;
XX
DR   WPI; 2000-647418/62.
XX
PT   New nucleic acid molecules encoding 62 human secreted proteins for
PT   diagnosing, preventing, treating or ameliorating medical conditions and
PT   used as food additives or preservatives -
XX
PS   Claim 11; Page 642-643; 716pp; English.
XX
CC   Sequences AAB38321-B38396 represent the amino acid sequences of 62
CC   human secreted proteins encoded by the genes AAC69512-C69587. The genes
CC   and proteins are useful for preventing, ameliorating or treating medical
CC   conditions, e.g. by protein or gene therapy. The genes are isolated from
CC   a range of human tissues disclosed in the specification. The nucleic
CC   acids, proteins, antibodies and (ant)agonists are useful in the
CC   diagnosis, treatment and prevention of: (a) autoimmune diseases e.g.
CC   rheumatoid arthritis; (b) hyperproliferative disorders e.g. neoplasms
CC   of the breast or liver; (c) cardiovascular disorders e.g. cardiac
CC   arrest; (d) cerebrovascular disorders e.g. cerebral ischemia; (e)
CC   angiogenesis; (f) nervous system disorders e.g. Alzheimer's disease; (g)
CC   infections caused by bacteria, viruses and fungi; and (h) ocular
CC   disorders e.g. corneal infection. The polypeptides can also be used to
CC   aid wound healing and epithelial cell proliferation, to prevent skin
CC   aging due to sunburn, to maintain organs before transplantation, for
CC   supporting cell culture of primary tissues, to regenerate tissues and in
CC   chemotaxis.
XX
SQ   Sequence   311 AA;

  Query Match             67.4%;  Score 209;  DB 21;  Length 311;
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 34
AAB38384
ID   AAB38384 standard; Protein; 311 AA.
XX
AC   AAB38384;
XX
DT   31-JAN-2001  (first entry)
XX
DE   Human secreted protein encoded by gene 13 clone HAPSA79.
XX
KW   Immunosuppressive; antiarthritic; antirheumatic; antiproliferative;
KW   cytostatic; cardiant; vasotropic; cerebroprotective; neuroprotective;
KW   nootropic; antibacterial; virucide; fungicide; opthalmalogical; human;
KW   vulnerary; gene therapy; infection; secreted protein.
XX
OS   Homo sapiens.
XX
PN   WO200061623-A1.
XX
PD   19-OCT-2000.
XX
PF   06-APR-2000; 2000WO-US08979.
XX
PR   09-APR-1999;   99US-0128693.
PR   26-APR-1999;   99US-0130991.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Ni J,  Komatsoulis GA,  Rosen CA,  Soppet DR,  Shi Y;
PI   Lafleur DW,  Olsen HS,  Ebner R,  Florence KA,  Moore PA,  Birse CE;
PI   Young PE;
XX
DR   WPI; 2000-647418/62.
XX
PT   New nucleic acid molecules encoding 62 human secreted proteins for
PT   diagnosing, preventing, treating or ameliorating medical conditions and
PT   used as food additives or preservatives -
XX
PS   Claim 11; Page 643-644; 716pp; English.
XX
CC   Sequences AAB38321-B38396 represent the amino acid sequences of 62
CC   human secreted proteins encoded by the genes AAC69512-C69587. The genes
CC   and proteins are useful for preventing, ameliorating or treating medical
CC   conditions, e.g. by protein or gene therapy. The genes are isolated from
CC   a range of human tissues disclosed in the specification. The nucleic
CC   acids, proteins, antibodies and (ant)agonists are useful in the
CC   diagnosis, treatment and prevention of: (a) autoimmune diseases e.g.
CC   rheumatoid arthritis; (b) hyperproliferative disorders e.g. neoplasms
CC   of the breast or liver; (c) cardiovascular disorders e.g. cardiac
CC   arrest; (d) cerebrovascular disorders e.g. cerebral ischemia; (e)
CC   angiogenesis; (f) nervous system disorders e.g. Alzheimer's disease; (g)
CC   infections caused by bacteria, viruses and fungi; and (h) ocular
CC   disorders e.g. corneal infection. The polypeptides can also be used to
CC   aid wound healing and epithelial cell proliferation, to prevent skin
CC   aging due to sunburn, to maintain organs before transplantation, for
CC   supporting cell culture of primary tissues, to regenerate tissues and in
CC   chemotaxis.
XX
SQ   Sequence   311 AA;

  Query Match             67.4%;  Score 209;  DB 21;  Length 311;
```

```
  Best Local Similarity   99.7%;  Pred. No. 1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 35
AAB80431
ID   AAB80431 standard; peptide; 339 AA.
XX
AC   AAB80431;
XX
DT   24-APR-2001  (first entry)
XX
DE   Gene #13 associated peptide #1.
XX
KW   Secreted protein; human; autoimmune; hyperproliferation;
KW   cardiovascular; cerebrovascular; infection; food.
XX
OS   Homo sapiens.
XX
PN   WO200107459-A1.
XX
PD   01-FEB-2001.
XX
PF   20-JUL-2000; 2000WO-US19735.
XX
PR   23-JUL-1999;   99US-0145220.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Ruben SM,  Ebner R,  Duan RD,  Ni J,  Soppet DR,  Moore PA;
PI   Shi Y,  Lafleur DW,  Olsen HS,  Birse CE,  Komatsoulis GA;
XX
DR   WPI; 2001-123261/13.
XX
PT   New isolated nucleic acid encoding 29 secreted proteins, for
PT   diagnosing, preventing and treating e.g. autoimmune,
PT   hyperproliferative, cardiovascular, and ocular diseases or disorders
PT   and microorganism infections -
XX
PS   Disclosure; Page 75; 601pp; English.
XX
CC   The present invention relates to 29 human secreted proteins. The
CC   invention is used to prevent autoimmune diseases e.g. rheumatoid
CC   arthritis, hyperproliferative disorders e.g. neoplasms of the
CC   breast or liver, cardiovascular disorders e.g. cardiac arrest,
CC   cerebrovascular disorders e.g. cerebral ischemia, angiogenesis,
CC   nervous system disorders e.g. Alzheimer's disease, infections
CC   caused by bacteria, viruses and fungi and ocular disorders e.g.
CC   corneal infection. Also used in food preparations.
XX
SQ   Sequence   339 AA;

  Query Match             67.4%;  Score 209;  DB 22;  Length 339;
  Best Local Similarity   99.7%;  Pred. No. 1.1e-196;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         30 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 89

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         90 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 149

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        150 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 209

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        210 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 269

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        270 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 329

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        330 DFRHKSSFVI 339


RESULT 36
ABP41902
ID   ABP41902 standard; Protein; 329 AA.
XX
AC   ABP41902;
XX
DT   22-AUG-2002  (first entry)
XX
DE   Human ovarian antigen HISAF60, SEQ ID NO:3034.
XX
KW   Human; ovarian antigen; ovary; ovarian; breast; cancer; tumour;
KW   ovarian cancer; breast cancer; tumour; reproductive system disorder;
KW   infertility; pregnancy disorder; anovulation; polycystic ovary syndrome;
KW   PCOS; ovarian cyst; dysmenorrhoea; endocrine disorder; infection;
KW   inflammatory condition; immune disorder; blood disorder;
KW   cardiovascular disorder; respiratory disorder; neurological disorder;
KW   gastrointestinal disorder; urinary system disorder; drug screening;
KW   gene therapy; chromosome mapping; forensic analysis;
KW   antibody preparation; cytostatic; immunomodulatory; neuroprotective;
KW   antiinflammatory; gynaecological; reproductive.
XX
OS   Homo sapiens.
XX
PN   WO200200677-A1.
XX
PD   03-JAN-2002.
XX
PF   07-JUN-2001; 2001WO-US18569.
XX
PR   07-JUN-2000; 2000US-209467P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Birse CE,  Rosen CA;
XX
DR   WPI; 2002-147878/19.
DR   N-PSDB; ABQ54979.
XX
PT   Isolated nucleic acid molecules encoding novel ovarian polypeptides,
PT   useful in the prevention, treatment and diagnosis of cancer (e.g.
PT   ovarian cancer), immune disorders, cardiovascular disorders and
```

```
PT   neurological diseases -
XX
PS   Claim 11; SEQ ID No 3034; 2922pp; English.
XX
CC   The invention relates to 2175 novel human ovarian antigens (ABP41054-
CC   ABP43228) and to cDNAs encoding them (ABQ54131-ABQ56305), and also
CC   encompasses polypeptides 90% identical and polynucleotides 95% identical
CC   to the sequences of the invention. The invention additionally relates to
CC   recombinant vectors and host cells comprising human ovarian antigen
CC   polynucleotides, antibodies against human ovarian antigens, and the use
CC   of ovarian antigen polynucleotides and polypeptides in diagnosing,
CC   treating, prognosing or preventing various ovary and/or breast-related
CC   disorders. Such conditions include ovarian cancer and breast cancer, and
CC   metastatic tumours of ovarian or breast origin, reproductive system
CC   disorders (e.g., infertility, disorders of pregnancy, anovulation,
CC   polycystic ovary syndrome, ovarian cysts, and dysmenorrhoea), endocrine
CC   disorders, infections (e.g., chlamydia, HIV, toxoplasmosis, and toxic
CC   shock syndrome), inflammatory conditions (e.g., mastitis, oophoritis and
CC   vaginitis), immune disorders (e.g., congenital and acquired
CC   immunodeficiencies, autoimmune oophoritis, systemic lupus erythematosus),
CC   blood-related disorders (e.g., anaemia), cardiovascular disorders,
CC   respiratory disorders, neurological disorders, gastrointestinal disorders
CC   and urinary system disorders. Ovarian antigen polypeptides and
CC   polynucleotides may also be used in screening for compounds which
CC   modulate ovarian antigen expression or activity. The polynucleotides may
CC   further be used for gene therapy, chromosome mapping, in the
CC   identification of individuals and in forensic analysis, and the
CC   polypeptides may be used as food additives or to prepare antibodies
CC   useful in disease diagnosis, drug targeting and phenotyping. The present
CC   sequence represents a human ovarian antigen of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   329 AA;

  Query Match            66.8%;  Score 207;  DB 23;  Length 329;
  Best Local Similarity  99.7%;  Pred. No. 1e-194;
  Matches  307;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          3 LRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQTSD 62
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         22 LRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQTSD 81

Qy         63 PRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVARND 122
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         82 PRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVARND 141

Qy        123 RKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPLPT 182
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        142 RKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPLPT 201

Qy        183 DSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDLNI 242
              |||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        202 DSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDLNI 261

Qy        243 GGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEGDF 302
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        262 GGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEGDF 321

Qy        303 RHKSSFVI 310
              ||||||||
Db        322 RHKSSFVI 329


RESULT 37
ABB06037
ID   ABB06037 standard; Protein; 321 AA.
XX
AC   ABB06037;
XX
DT   10-MAY-2002  (first entry)
XX
DE   Human NS protein sequence SEQ ID NO:129.
XX
KW   Human; cytostatic; osteopathic; gynaecological; neuroprotective;
KW   antirheumatic; antiarthritic; antipsoriatic; ophthalmological; anti-HIV;
KW   vasotropic; antiarteriosclerotic; antiinflammatory; dermatological;
KW   anorectic; muscular; antiinfertility; cardiovascular; anticoagulant;
KW   antifibrinolytic; hypotension; antiasthmatic; immunomodulator; cardiant;
KW   anticonvulsant; antidiabetic; tranquilliser; antidepressant; aeuroleptic;
KW   gastrointestinal; virucide; antiulcer; cerebroprotective; nootropic;
KW   contraceptive; vaccine; gene therapy; cancer; osteoporosis; dystonia;
KW   endometriosis; degenerative disease; multiple sclerosis; psoriasis;
KW   rheumatoid arthritis; cataract; restenosis; atherosclerosis; glaucoma;
KW   inflammation; skin disorder; obesity; muscular dystrophy; AIDS;
KW   infertility; cardiovascular disease; coagulation disease; hypertension;
KW   ischaemia; asthma; immune disease; epilepsy; angina; neurodegeneration;
KW   diabetes; anxiety; depression; schizophrenia; viral disease; stroke;
KW   gastric ulcer; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
PN   WO200206315-A2.
XX
PD   24-JAN-2002.
XX
PF   17-JUL-2001; 2001WO-IL00653.
XX
PR   18-JUL-2000; 2000IL-0137345.
PR   15-DEC-2000; 2000IL-0140354.
XX
PA   (COMP-) COMPUGEN LTD.
XX
PI   Mintz L,  Freilich S,  Bernstein J;
XX
DR   WPI; 2002-155037/20.
DR   N-PSDB; ABL39691.
XX
PT   One hundred and twenty eight novel nucleic acid sequences, useful for
PT   treating and diagnosing e.g. cancer, asthma and Alzheimer's -
XX
PS   Claim 6; Page 148-149; 290pp; English.
XX
CC   ABL39691 to ABL39818 represent novel human nucleic acid sequences
CC   encoding the proteins given in ABB06037 to ABB06164. The novel sequences
CC   (NS) can have cytostatic, osteopathic, gynaecological, neuroprotective,
CC   antirheumatic, antiarthritic, antipsoriatic, ophthalmological, virucide,
CC   vasotropic, antiarteriosclerotic, antiinflammatory, dermatological,
CC   anorectic, muscular, anti-HIV, antiinfertility, cardiovascular,
CC   anticoagulant, antifibrinolytic, hypotension, antiasthmatic, cardiant,
CC   immunomodulator, anticonvulsant, antidiabetic, tranquilliser, antiulcer,
CC   antidepressant, gastrointestinal, aeuroleptic, cerebroprotective,
CC   nootropic and contraceptive activities. The NS can be used in vaccines,
CC   gene therapy and antisense therapy. Nucleic acids, expression vectors and
CC   antibodies from the present invention can be used for treating and
CC   diagnosing e.g. cancer, osteoporosis, endometriosis, degenerative
CC   diseases, dystonia, multiple sclerosis, rheumatoid arthritis, psoriasis,
CC   cataracts, restenosis, atherosclerosis, inflammation, skin disorders,
CC   glaucoma, obesity, muscular dystrophy, AIDS, infertility, cardiovascular
CC   disease, coagulation disease, ischaemia, hypertension, asthma, immune
CC   disease, epilepsy, angina, neurodegeneration, diabetes, anxiety,
CC   depression, schizophrenia, viral disease, gastric ulcers, stroke,
CC   Alzheimer's disease and as a contraceptive.
XX
SQ   Sequence   321 AA;

  Query Match            44.8%;  Score 139;  DB 23;  Length 321;
  Best Local Similarity  100.0%;  Pred. No. 6.4e-128;
  Matches  139;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 ALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQTS 61
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         20 ALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQTS 79

Qy         62 DPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVARN 121
```

```
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          80 DPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVARN 139

Qy         122 DRKEIDEIVIELTVQVKPV 140
               ||||||||||||||||||||
Db         140 DRKEIDEIVIELTVQVKPV 158


RESULT 38
AAB39254
ID   AAB39254 standard; Protein; 285 AA.
XX
AC   AAB39254;
XX
DT   02-FEB-2001  (first entry)
XX
DE   Human secreted protein sequence encoded by gene 15 SEQ ID NO:134.
XX
KW   Human; secreted protein; immunosuppressive; antiarthritic; antirheumatic;
KW   antiproliferative; cytostatic; cardiant; vasotropic; cerebroprotective;
KW   nootropic; neuroprotective; antibacterial; virucide; fungicide; neoplasm;
KW   opthalmalogical; autoimmune disease; rheumatoid arthritis; angiogenesis;
KW   hyperproliferative disorder; cardiovascular disorder; infection;
KW   cerebrovascular disorder; nervous system disorder; ocular disorder;
KW   wound healing; chemotaxis.
XX
OS   Homo sapiens.
XX
PN   WO200056754-A1.
XX
PD   28-SEP-2000.
XX
PF   16-MAR-2000; 2000WO-US06792.
XX
PR   19-MAR-1999;  99US-0125362.
PR   10-DEC-1999;  99US-0169980.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen GA,  Ruben SM,  Komatsoulis G;
XX
DR   WPI; 2000-579483/54.
DR   N-PSDB; AAC74237.
XX
PT   Isolated nucleic acid molecule encoding a human secreted protein is
PT   used in preventing, treating or ameliorating a medical condition  -
XX
PS   Disclosure; Page 32; 434pp; English.
XX
CC   The polynucleotide sequences given in AAC74223-C74279 encode the human
CC   secreted proteins represented in AAB39179-B39226. Sequences
CC   AAB39227-B39308 are alternative proteins encoded by the genes, and also
CC   protein sequences with which they share homology. The proteins have
CC   activities based on the tissues and cells in which they are expressed.
CC   Examples of activities include: immunosuppressive; antiarthritic;
CC   antirheumatic; antiproliferative; cytostatic; cardiant; vasotropic;
CC   cerebroprotective; nootropic; neuroprotective; antibacterial; virucide;
CC   fungicide; and opthalmalogical. The human secreted proteins,
CC   polynucleotides, antagonists and agonists of the invention may be useful
CC   in the treatment, prevention, and/or diagnosis of various disease,
CC   disorders and conditions such as autoimmune diseases e.g. rheumatoid
CC   arthritis, hyperproliferative disorders e.g. neoplasms of the breast or
CC   liver, cardiovascular disorders e.g. cardiac arrest, cerebrovascular
CC   disorders e.g. cerebral ischaemia, angiogenesis, nervous system disorders
CC   e.g. Alzheimer's disease, infections caused by bacteria, viruses and
CC   fungi and ocular disorders e.g. corneal infection. The polypeptides can
CC   also be used to aid wound healing and epithelial cell proliferation, to
CC   regenerate tissues, maintain organs before transplantation, in
CC   chemotaxis and as a food additive or preservative e.g. to increase
CC   storage capabilities. Sequences AAC74214-C74222 and AAB39178 are used
CC   during the isolation and characterisation of the genes of the invention.
XX
SQ   Sequence   285 AA;

  Query Match             37.1%;  Score 115;  DB 21;  Length 285;
  Best Local Similarity   100.0%;  Pred. No. 2.2e-104;
  Matches  115;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         196 HLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDLNIGGIIGGVLVVLAV 255
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         171 HLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDLNIGGIIGGVLVVLAV 230

Qy         256 LALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEGDFRHKSSFVI 310
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         231 LALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEGDFRHKSSFVI 285


RESULT 39
AAO16453
ID   AAO16453 standard; protein; 310 AA.
XX
AC   AAO16453;
XX
DT   17-APR-2003  (first entry)
XX
DE   Human junctional adhesion molecule 3 (huJAM3).
XX
KW   Human; gene therapy; extracellular region; junctional adhesion molecules;
KW   huJAM; immune system disorder; immune deficiency; autoimmune disorder;
KW   inflammatory disorder; cancer; wound healing; cardiovascular disease;
KW   full-length membrane-bound huJAM protein.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..30
FT                   /label= Signal_peptide
FT   Misc-difference 15
FT                   /note= "Encoded by ATG"
FT   Domain          31..240
FT                   /note= "Extracellular domain; Specifically claimed
FT                   region"
FT   Protein         31..310
FT                   /note= "Mature huJAM3"
FT   Misc-difference 46
FT                   /note= "Encoded by TTT"
FT   Misc-difference 87
FT                   /note= "Encoded by AGAC"
FT   Misc-difference 136
FT                   /note= "Encoded by CAA"
FT   Misc-difference 191
FT                   /note= "Encoded by GC"
FT   Misc-difference 195
FT                   /note= "Encoded by TCC"
XX
PN   WO2003008541-A2.
XX
PD   30-JAN-2003.
XX
PF   05-JUL-2002; 2002WO-US19800.
XX
PR   16-JUL-2001; 2001US-305752P.
PR   05-FEB-2002; 2002US-354345P.
XX
PA   (ELIL ) LILLY & CO ELI.
XX
PI   Heuer JG,  Smith RC,  Su EW;
XX
DR   WPI; 2003-221848/21.
DR   N-PSDB; AAL51600.
XX
PT   New extracellular human junctional adhesion molecule (huJAM)
PT   polypeptide, useful for treating an immune system disorder such as an
PT   immune deficiency or an inflammatory disorder, cancer, wound healing,
PT   or a cardiovascular disease  -
XX
```

PS Disclosure; Fig 1; 131pp; English.
XX
CC The invention comprises the DNA and protein sequences of the
CC extracellular region of human junctional adhesion molecules (huJAM). The
CC extracellular huJAM DNA and protein sequences are useful in the treatment
CC of: immune system disorders (e.g. immune deficiency); autoimmune
CC disorders; inflammatory disorders; cancer; wound healing; or a
CC cardiovascular disease. The present amino acid sequence represents the
CC full-length membrane-bound huJAM3 protein.
XX
SQ Sequence 310 AA;

Query Match 37.1%; Score 115; DB 24; Length 310;
Best Local Similarity 100.0%; Pred. No. 2.3e-104;
Matches 115; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 196 HLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDLNIGGIIGGVLVVLAV 255
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 196 HLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDLNIGGIIGGVLVVLAV 255

Qy 256 LALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEGDFRHKSSFVI 310
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 256 LALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEGDFRHKSSFVI 310

RESULT 40
ABG04645
ID ABG04645 standard; Protein; 291 AA.
XX
AC ABG04645;
XX
DT 13-FEB-2002 (first entry)
XX
DE Novel human diagnostic protein #4636.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US08631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR N-PSDB; AAS68832.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 20; SEQ ID No 35004; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. ABG00010-ABG30377 represent novel human
CC diagnostic amino acid sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 291 AA;

Query Match 34.8%; Score 108; DB 22; Length 291;
Best Local Similarity 100.0%; Pred. No. 1.7e-97;
Matches 108; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 87 DLAGRAEILGKTSLKIWNVTRRDSALYRCEVVARNDRKEIDEIVIELTVQVKPVTPVCRV 146
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 134 DLAGRAEILGKTSLKIWNVTRRDSALYRCEVVARNDRKEIDEIVIELTVQVKPVTPVCRV 193

Qy 147 PKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPLPTDSRANPRFRNSS 194
|||||||||||||||||||||||||||||||||||||||||||||||||||
Db 194 PKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPLPTDSRANPRFRNSS 241

RESULT 41
ABG12109
ID ABG12109 standard; Protein; 404 AA.
XX
AC ABG12109;
XX
DT 18-FEB-2002 (first entry)
XX
DE Novel human diagnostic protein #12100.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US08631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR N-PSDB; AAS76296.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 20; SEQ ID No 42468; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or

```
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. ABG00010-ABG30377 represent novel human
CC   diagnostic amino acid sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   404 AA;

  Query Match             34.8%;  Score 108;  DB 22;  Length 404;
  Best Local Similarity   100.0%;  Pred. No. 2.2e-97;
  Matches  108;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         87 DLAGRAEILGKTSLKIWNVTRRDSALYRCEVVARNDRKEIDEIVIELTVQVKPVTPVCRV 146
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        134 DLAGRAEILGKTSLKIWNVTRRDSALYRCEVVARNDRKEIDEIVIELTVQVKPVTPVCRV 193

Qy        147 PKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPLPTDSRANPRFRNSS 194
              ||||||||||||||||||||||||||||||||||||||||||||||||
Db        194 PKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPLPTDSRANPRFRNSS 241


RESULT 42
ABG22401
ID   ABG22401 standard; Protein; 361 AA.
XX
AC   ABG22401;
XX
DT   18-FEB-2002  (first entry)
XX
DE   Novel human diagnostic protein #22392.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0540217.
PR   23-AUG-2000; 2000US-0649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT,  Liu C,  Tang YT;
XX
DR   WPI; 2001-639362/73.
DR   N-PSDB; AAS86588.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity  -
XX
PS   Claim 20; SEQ ID No 52760; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. ABG00010-ABG30377 represent novel human
CC   diagnostic amino acid sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   361 AA;

  Query Match             33.5%;  Score 104;  DB 22;  Length 361;
  Best Local Similarity   100.0%;  Pred. No. 1.7e-93;
  Matches  104;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         26 GCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQTSDPRIEWKKIQDEQTTYVFFDNKIQ 85
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         35 GCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQTSDPRIEWKKIQDEQTTYVFFDNKIQ 94

Qy         86 GDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVARNDRKEIDEI 129
              |||||||||||||||||||||||||||||||||||||||||||||
Db         95 GDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVARNDRKEIDEI 138


RESULT 43
AAY11472
ID   AAY11472 standard; Protein; 89 AA.
XX
AC   AAY11472;
XX
DT   21-JUN-1999  (first entry)
XX
DE   Human 5' EST secreted protein SEQ ID No 294.
XX
KW   Human; secreted protein; EST; expressed sequence tag; diagnosis;
KW   forensic; gene therapy; chromosome mapping; signal peptide;
KW   upstream regulatory sequence; cytokine activity; cell proliferation;
KW   differentiation; haematopoiesis regulation; tissue growth regulation;
KW   reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
KW   thrombolytic; anti-inflammatory; tumour inhibition.
XX
OS   Homo sapiens.
XX
PN   WO9906551-A2.
XX
PD   11-FEB-1999.
XX
PF   31-JUL-1998;   98WO-IB01235.
XX
PR   01-AUG-1997;   97US-0905133.
XX
PA   (GEST ) GENSET.
XX
PI   Duclert A,  Dumas Milne Edwards J,  Lacroix B;
XX
DR   WPI; 1999-153781/13.
DR   N-PSDB; AAX39538.
XX
PT   New nucleic acids encoding human secreted - proteins obtained from
PT   cDNA libraries prepared from substantia nigra, cerebellum, surrenals
PT   and fetal brain tissue
XX
PS   Claim 34; Page 394; 434pp; English.
XX
CC   AAX39440 to AAX39597 represent 5' expressed sequence tags (ESTs) for
CC   human secreted proteins, and encode the proteins given in AAY11374 to
```

CC AAY11531, respectively. The proteins given represent the signal peptide
CC and an N-terminal fragment of a secreted protein. The nucleic acid
CC sequences can be used for producing secreted human gene products. They
CC can also be used to develop products for diagnosis and therapy. The
CC proteins obtained may have cytokine activity, cell
CC proliferation/differentiation activity, haematopoiesis regulating
CC activity, tissue growth regulating activity, reproductive hormone
CC regulating activity, chemotactic/ chemokinetic activity, haemostatic and
CC thrombolytic activity, receptor/ ligand activity, anti-inflammatory
CC activity, tumour inhibition activity or other activities. The products
CC can be used in forensic, gene therapy and chromosome mapping procedures.
CC The sequences can also be used for obtaining corresponding promoter
CC sequences. The nucleic acids encoding the signal peptide can be used for
CC directing extracellular secretion of a polypeptide or the insertion of a
CC polypeptide into a membrane, or importing a polypeptide into a cell.
XX
SQ Sequence 89 AA;

Query Match 28.7%; Score 89; DB 20; Length 89;
Best Local Similarity 100.0%; Pred. No. 2.8e-79;
Matches 89; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLA 89
              ||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLA 89
```

RESULT 44
ABG27038
ID ABG27038 standard; Protein; 267 AA.
XX
AC ABG27038;
XX
DT 18-FEB-2002 (first entry)
XX
DE Novel human diagnostic protein #27029.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US08631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR N-PSDB; AAS91225.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 20; SEQ ID No 57397; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. ABG00010-ABG30377 represent novel human
CC diagnostic amino acid sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 267 AA;

Query Match 20.3%; Score 63; DB 22; Length 267;
Best Local Similarity 100.0%; Pred. No. 2.5e-53;
Matches 63; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        239 DLNIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDE 298
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        130 DLNIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDE 189

Qy        299 EGD 301
              |||
Db        190 EGD 192
```

RESULT 45
ABG07157
ID ABG07157 standard; Protein; 264 AA.
XX
AC ABG07157;
XX
DT 13-FEB-2002 (first entry)
XX
DE Novel human diagnostic protein #7148.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US08631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR N-PSDB; AAS71344.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 20; SEQ ID No 37516; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,

CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. ABG00010-ABG30377 represent novel human
CC diagnostic amino acid sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 264 AA;

Query Match 16.5%; Score 51; DB 22; Length 264;
Best Local Similarity 100.0%; Pred. No. 1.5e-41;
Matches 51; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 86 GDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVARNDRKEIDEIVIELTVQ 136
||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 214 GDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVARNDRKEIDEIVIELTVQ 264

RESULT 46
ABG22399
ID ABG22399 standard; Protein; 301 AA.
XX
AC ABG22399;
XX
DT 18-FEB-2002 (first entry)
XX
DE Novel human diagnostic protein #22390.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US08631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR N-PSDB; AAS86586.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 20; SEQ ID No 52758; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. ABG00010-ABG30377 represent novel human
CC diagnostic amino acid sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 301 AA;

Query Match 16.5%; Score 51; DB 22; Length 301;
Best Local Similarity 100.0%; Pred. No. 1.7e-41;
Matches 51; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 86 GDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVARNDRKEIDEIVIELTVQ 136
||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 214 GDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVARNDRKEIDEIVIELTVQ 264

RESULT 47
ABG22398
ID ABG22398 standard; Protein; 68 AA.
XX
AC ABG22398;
XX
DT 18-FEB-2002 (first entry)
XX
DE Novel human diagnostic protein #22389.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US08631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR N-PSDB; AAS86585.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 20; SEQ ID No 52757; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques

```
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. ABG00010-ABG30377 represent novel human
CC   diagnostic amino acid sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   68 AA;

  Query Match             12.3%;  Score 38;  DB 22;  Length 68;
  Best Local Similarity   100.0%;  Pred. No. 2.9e-29;
  Matches   38;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         49 VELSCIITDSQTSDPRIEWKKIQDEQTTYVFFDNKIQG 86
              |||||||||||||||||||||||||||||||||||||
Db         28 VELSCIITDSQTSDPRIEWKKIQDEQTTYVFFDNKIQG 65


RESULT 48
AAB27272
ID   AAB27272 standard; Protein; 310 AA.
XX
AC   AAB27272;
XX
DT   23-FEB-2001  (first entry)
XX
DE   Human confluency regulated adhesion molecule 1 #1.
XX
KW   Immunoglobulin superfamily; Ig Sf; vascular adhesion molecule;
KW   inflammation; cancer; wound; angiogenesis; human;
KW   confluency regulated adhesion molecule 1; CRAM-1; JAM-2.
XX
OS   Homo sapiens.
XX
PN   WO200053749-A2.
XX
PD   14-SEP-2000.
XX
PF   13-MAR-2000; 2000WO-EP02219.
XX
PR   11-MAR-1999;   99EP-0200746.
XX
PA   (RMFD-) RMF DICTAGENE SA.
XX
PI   Imhof BA,  Aurrand-Lions M;
XX
DR   WPI; 2000-587436/55.
XX
PT   Isolated human Confluency Regulated Adhesion Molecule 1 or 2 (CRAM-1 or
PT   CRAM-2) polypeptide, useful for treatment of tumors, inflammation
PT   reactions and modulating vascular permeability -
XX
PS   Claim 1; Fig 3; 59pp; English.
XX
CC   The present sequence is the human confluency regulated adhesion molecule
CC   1 (CRAM-1, also known as JAM-2). CRAM-1 is one of the vascular adhesion
CC   proteins of the immunoglobulin superfamily (Ig Sf). The CRAM-1 protein
CC   and coding sequence can be used in the treatment of cancer,
CC   inflammation, to modulate cell-cell interactions and angiogenesis, and
CC   in the modulation of wound healing.
XX
SQ   Sequence   310 AA;

  Query Match             7.7%;  Score 24;  DB 21;  Length 310;
  Best Local Similarity   100.0%;  Pred. No. 5.9e-15;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        167 PRPHYSWYRNDVPLPTDSRANPRF 190
              ||||||||||||||||||||||||
Db        167 PRPHYSWYRNDVPLPTDSRANPRF 190


RESULT 49
AAB27278
ID   AAB27278 standard; Protein; 310 AA.
XX
AC   AAB27278;
XX
DT   23-FEB-2001  (first entry)
XX
DE   Murine confluency regulated adhesion molecule 1.
XX
KW   Immunoglobulin superfamily; Ig Sf; vascular adhesion molecule;
KW   inflammation; cancer; wound; angiogenesis; mouse;
KW   confluency regulated adhesion molecule 1; CRAM-1; JAM-2.
XX
OS   Mus sp.
XX
PN   WO200053749-A2.
XX
PD   14-SEP-2000.
XX
PF   13-MAR-2000; 2000WO-EP02219.
XX
PR   11-MAR-1999;   99EP-0200746.
XX
PA   (RMFD-) RMF DICTAGENE SA.
XX
PI   Imhof BA,  Aurrand-Lions M;
XX
DR   WPI; 2000-587436/55.
DR   N-PSDB; AAA97189.
XX
PT   Isolated human Confluency Regulated Adhesion Molecule 1 or 2 (CRAM-1 or
PT   CRAM-2) polypeptide, useful for treatment of tumors, inflammation
PT   reactions and modulating vascular permeability -
XX
PS   Example; Fig 8; 59pp; English.
XX
CC   The present sequence is the murine confluency regulated adhesion molecule
CC   1 (CRAM-1, also known as JAM-2). CRAM-1 is one of the vascular adhesion
CC   proteins of the immunoglobulin superfamily (Ig Sf). The CRAM-1 protein
CC   and coding sequence can be used in the treatment of cancer, inflammation,
CC   to modulate cell-cell interactions and angiogenesis, and in the
CC   modulation of wound healing.
XX
SQ   Sequence   310 AA;

  Query Match             7.7%;  Score 24;  DB 21;  Length 310;
  Best Local Similarity   100.0%;  Pred. No. 5.9e-15;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        167 PRPHYSWYRNDVPLPTDSRANPRF 190
              ||||||||||||||||||||||||
Db        167 PRPHYSWYRNDVPLPTDSRANPRF 190


RESULT 50
ABG49183
ID   ABG49183 standard; Peptide; 31 AA.
XX
AC   ABG49183;
XX
DT   25-FEB-2003  (first entry)
XX
DE   Human liver peptide, SEQ ID No 27831.
XX
```

KW Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW hypercholesterolaemia; coronary heart disease.
XX
OS Homo sapiens.
XX
PN WO200157273-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00664.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488898/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for
PT analysing gene expression in human adult liver -
XX
PS Claim 27; SEQ ID No 27831; 658pp; English.
XX
CC The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC measuring human gene expression in a sample derived from human adult
CC liver, comprising one of 13109 defined nucleotide sequences given in the
CC specification (or complements/ fragments). The probe hybridises at high
CC stringency to a nucleic acid molecule expressed in the human adult
CC liver. (I) may be used for predicting, measuring and displaying gene
CC expression in samples derived from human adult liver. The genes
CC identified may be involved in genetic liver diseases such as cirrhosis,
CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which
CC is associated with coronary heart disease. ABG47348-ABG59930 represent
CC human liver single exon encoded peptides of the invention.
CC Note: The sequence information for this patent does not appear in the
CC printed specification but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 31 AA;

Query Match 2.6%; Score 8; DB 22; Length 31;
Best Local Similarity 100.0%; Pred. No. 4.4;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        249 VLVVLAVL 256
              ||||||||
Db         10 VLVVLAVL 17
```

Search completed: December 15, 2003, 14:58:59
Job time : 44 secs